

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
23 December 2004 (23.12.2004)

PCT

(10) International Publication Number
WO 2004/111652 A1

(51) International Patent Classification⁷: **G01N 33/68**,
33/92, C12Q 1/68, A61K 31/00, 38/00, 39/00 // C07K
14/775

(21) International Application Number:
PCT/EP2004/051170

(22) International Filing Date: 18 June 2004 (18.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03101795.7 19 June 2003 (19.06.2003) EP

(71) Applicant (for all designated States except US): **AP-
PLIED RESEARCH SYSTEMS ARS HOLDING N.V.**
[NL/NL]; Pietermaai 15, Curacao (AN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SOTO-JARA, Clau-
dio** [CL/US]; 2403 Pine Drive, Friendswood, TX 77546
(US). **MAUNDRELL, Kinsey** [GB/CH]; 16, Chemin de
la Gradelle, CH-1224 Geneva (CH).

(74) Agent: **SERONO INTERNATIONAL SA INTELLEC-
TUAL PROPERTY DEPARTMENT HASSA, JUER-
GEN**; 12, Chemin des Aulx, CH-1228 Plan-les-Ouates
(CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments
- with sequence listing part of description published sepa-
rately in electronic form and available upon request from
the International Bureau

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: USE OF PRION CONVERSION MODULATING AGENTS

(57) Abstract: The use of Apolipoprotein B, Apolipoprotein E, fragments and mimetics thereof is provided for diagnostic, detection, prognostic and therapeutic applications in prion diseases. More specifically, the invention provides the use of Apolipoprotein B or fragments thereof for modulating or identifying modulators of the prion protein replication which are implicated in the pathogenesis of transmissible spongiform encephalopathies and other prion diseases.

USE OF PRION CONVERSION MODULATING AGENTS

Field of the invention

This invention relates to the use of apolipoprotein B or apolipoprotein E or
5 fragments or mimetics thereof for diagnostic, detection, prognostic and identifying
modulators of the prion protein replication. More specifically, the invention provides
the use of modulators of apolipoprotein B or fragments thereof for modulating the prion
protein replication which are implicated in the pathogenesis of transmissible spongiform
encephalopathies and other prion diseases.

10

Background of the invention

Creutzfeldt-Jakob disease (CJD) in humans and scrapie and bovine spongiform
encephalopathy (BSE) in animals are some of the diseases that belong to the group of
Transmissible Spongiform Encephalopathies (TSE), also known as prion diseases
15 (*Prusiner, 1991*). These diseases are characterized by an extremely long incubation
period, followed by a brief and invariably fatal clinical disease (*Roos et al., 1973*). To
date no therapy is available.

Although these diseases are relatively rare in humans, the risk for the transmissibility of
20 BSE to humans through the food chain has seized the attention of the public health
authorities and the scientific community (*Soto et al., 2001*). Variant CJD (vCJD) is a
new disease, which was first described in March 1996 (*Will et al., 1996*). In contrast to
typical cases of sporadic CJD (sCJD), this variant form affects young patients (average
age 27 years old) and has a relatively long duration of illness (median 14 months vs. 4.5
25 months in traditional CJD). A link between vCJD and BSE was first hypothesized
because of the association of these two TSEs in place and time (*Bruce, 2000*). The most
recent and powerful evidence comes from studies showing that the transmission
characteristics of BSE and vCJD to mice are almost identical and strongly indicating
that they are due to the same causative agent (*Bruce et al., 1997*). Moreover, transgenic
30 mice carrying a human or a bovine gene have now been shown to be susceptible to BSE
and vCJD (*Scott et al., 1999*). Furthermore, no other plausible hypothesis for the
occurrence of vCJD has been proposed and intensive CJD surveillance in five European

countries, with a low exposure to the BSE agent, has failed to identify any additional cases. In conclusion, the most likely cause of vCJD is exposure to the BSE agent, probably due to dietary contamination with affected bovine central nervous system tissue.

5

The nature of the transmissible agent has been matter of passionate controversy. Further research, has indicated that the TSE agent differs significantly from viruses and other conventional agents in that it seems not to contain nucleic acids (*Prusiner, 1998*). Additionally, the physicochemical procedures that inactivate most viruses, such as
10 disrupting nucleic acids, have proved ineffective in decreasing the infectivity of the TSE pathogen. In contrast, the procedures that degrade protein have been found to inactivate the pathogen (*Prusiner, 1991*). Accordingly, the theory that proposes that the transmissible agent is neither a virus nor other previously known infectious agent, but rather an unconventional agent consisting only of a protein recently gained widespread
15 acceptability (*Prusiner, 1998*). This new class of pathogen was called a "prion", short for "proteinaceous infectious particle". In TSE, prions are composed mainly of a misfolded protein named PrP^{Sc} (for scrapie PrP), which is a post-translationally modified version of a normal protein, termed PrP^C (*Cohen et al., 1998*). Chemical differences have not been detected to distinguish these two PrP isoforms and the
20 conversion seems to involve a conformational change whereby the α -helical content of the normal protein diminishes and the amount of β -sheet increases (*Pan et al., 1993*). The structural changes are followed by alterations in the biochemical properties: PrP^C is soluble in non-denaturing detergents, PrP^{Sc} is insoluble; PrP^C is readily digested by proteases (also called protease sensitive prion protein) while PrP^{Sc} is partially resistant,
25 resulting in the formation of a N-terminally truncated fragment known as PrPres (protease resistant prion protein) (*Cohen et al., 1998*).

The notion that endogenous PrP^C is involved in the development of infection is supported by experiments in which endogenous PrP gene was knocked out where the animals were both resistant to prion disease and unable to generate new infectious
30 particles (*Bueler et al., 1993*). In addition, it is clear that during the time between the inoculation with the infectious protein and the appearance of the clinical symptoms, there is a dramatic increase in the amount of PrP^{Sc}.

These findings suggest that endogenous PrP^C is converted to PrP^{Sc} conformation by the action of an infectious form of the PrP molecule (*Soto et al., 2001*). Prion replication is hypothesized to occur when PrP^{Sc} in the infecting inoculum interacts specifically with host PrP^C, catalyzing its conversion to the pathogenic form of the protein. A physical association between the two isoforms during the infectious process is suggested by the primary sequence specificity in prion transmission (*Telling et al., 1994*) and by the reported *in vitro* generation of PrP^{Sc}-like molecules by mixing purified PrP^C with PrP^{Sc} (*Saborio et al., 2001*). However, the exact mechanism underlying the conversion is not known.

Investigations with chimeric transgenes showed that PrP^C and PrP^{Sc} are likely to interact within a central domain delimited by codons 96 and 169 (*Prusiner, 1996*) and synthetic PrP peptides spanning the region 109-141 proved to be able to bind to PrP^C and compete with PrP^{Sc} interaction (*Chabry et al., 1998*).

Based on data with transgenic animals, it has been proposed that additional brain factors present in the host are essential for prion propagation (*Telling et al., 1995*). It has been demonstrated previously that prion conversion does not occur under experimental conditions where purified PrP^C and PrP^{Sc} are mixed and incubated (*Saborio et al., 1999*) but that the conversion activity is recovered when the bulk of cellular proteins are added back to the sample (*Saborio et al., 1999*). This finding provides direct evidence that other factors present in the brain are essential to catalyse prion propagation.

The observation that cholesterol depletion decreases the formation of PrP^{Sc} whereas sphingolipid depletion increases PrP^{Sc} formation, suggested that "lipid rafts" (lipid domains in membranes that contain sphingolipids and cholesterol) may be the site of the PrP^C to PrP^{Sc} conversion reaction involving either a raft-associated protein or selected raft lipids (*Fantini et al., 2002*). However, the role of lipid rafts in prion infectivity is still unclear.

Several *in vitro* methods of detections of prions in a sample have been developed. The set of known detection methods, include PrP^{Sc} detection methods using specific ligand carriers selected from aminoglycans, fibronectin and Apolipoprotein A (*WO*

02/065133); methods using the monoclonal antibodies selected from G8138, 3B5 and 12F10 (*Schulz et al., 2000*); methods based on the formation of a complex between PrP^{Sc} and Apolipoprotein H (*WO 03/005037*); or methods based on the PrP^{Sc} *in vitro* amplification called protein misfolding cyclic amplification (PMCA) described in
5 *Saborio et al., 2001* and *Lucassen et al., 2003*.

Apolipoprotein B is the major protein component of the two known atherogenic lipoproteins, Low Density Lipoproteins (LDL) and remnants of triglyceride-rich lipoproteins. The apolipoprotein B concentration is considered to be a direct reflection
10 of the number of atherogenic particles in the blood and has been proposed as a parameter for determining the risk of atherosclerosis.

Apolipoprotein E is a constituent of several plasma lipoprotein such as chylomicrons, very low-density lipoproteins (VLDL), and high-density lipoproteins (HDL) (*Lehninger*
15 *et al., 1993*).

Apolipoprotein E has recently emerged as a major genetic risk factor for Alzheimer's disease, a neurodegenerative disorder (*US 6,022,683*) and upregulated in the cerebrospinal fluid of patients with variant CJD and Alzheimer's disease compared to patients with sporadic CJD (*Choe et al., 2002*). The Apolipoprotein E 4/4 phenotype is
20 associated with increased risk of coronary heart diseases and Creutzfeld-Jakob disease (*Golaz et al., 1995*). Apolipoprotein E gene expression was found to be increased in astrocytes associated with the neuropathological lesions in a scrapie animal model (*Dietrich et al., 1991*).

Apolipoprotein E was found to recognise a shared structural motif of amyloids and prion which, after induction, can accelerate the adoption of a beta-sheet conformation
25 (*Baumann et al., 2000*).

Apolipoprotein B and E are ligands for the LDL receptor and are known for its prominent role in cholesterol transport and plasma lipoprotein metabolism via LDL
30 receptor interactions (*Segrest et al., 2001*; *Clavey et al., 1991*).

One approach to the treatment and prevention of prion diseases has been to develop agents for blocking the transformation of PrP^c into PrP^{Sc}. Some agents proposed were Congo red dye (*US 5,276,059*), nerve growth peptides (*US 5,134,121*), fragments of prion proteins (*US 6,355,610*), compounds that reduces Apolipoprotein E release in the
5 brain tissue (*US 2002/0155426*), therapeutic agents that prevent Apolipoprotein E4 to interact with neuronal LDL receptor-related protein (*WO 97/14437*), compounds that increase Apolipoprotein E levels (*WO 99/15159*) and beta-sheet breaker peptides (*US 5,948,763*).

It would be desirable to develop new methods for identifying and inhibiting the prion
10 conversion factor(s).

Summary of the invention

It is an object of the invention to provide a use of peptides or proteins in an assay for the detection of PrP^{Sc} formation in a sample.

15 It is also an object of the invention to provide a use of peptides or proteins in a screening assay for identifying compounds that modulate the conversion of PrP^c into PrP^{Sc}.

20 It is further an object of the invention to provide a substance which is suitable for the treatment of, and/or prevention of, and/or delaying the progression of prion related disorders, notably, bovine spongiform encephalopathy (BSE) and Creutzfeld-Jacob Disease (CJD).

25 In a first aspect, the invention provides a use of a peptide or a protein selected from Apolipoprotein B; a fragment or mimetic thereof; Apolipoprotein E and a fragment or mimetic thereof, in an assay for the detection of PrP^{Sc} formation in a sample.

In a second aspect, the invention provides a use of a peptide or a protein selected from
30 Apolipoprotein B; a fragment or mimetic thereof; Apolipoprotein E and a fragment or mimetic thereof, in a screening assay for identifying compounds that modulate the conversion of PrP^c into PrP^{Sc}.

In a third aspect, the invention provides a use of a modulator, preferably an inhibitor or an antagonist, of a peptide or a protein, wherein the peptide or the protein is selected from Apolipoprotein B; a fragment and a mimetic thereof, for the preparation of a pharmaceutical composition for the treatment of a prion disease, notably, bovine spongiform encephalopathy (BSE) and a Creutzfeld-Jacob Disease (CJD).

In a fourth aspect, the invention provides a method for the diagnosis or detection of a prion disease within a subject suspected of suffering from such a disease which comprises (i) contacting a sample from said subject with a peptide or a protein selected from Apolipoprotein B; a fragment or a mimetic thereof; Apolipoprotein E; a fragment thereof and a mimetic thereof; (ii) contacting the sample obtained from step (i) with PrP^C or PrP^C containing mixtures, such as brain homogenates, cell lysates, lipid rafts preparation; and (iii) determining the presence and/or amount of PrP^{Sc} in said sample.

In a fifth aspect, the invention provides a method of determining a marker that predisposes a subject to a prion disease, comprising (i) measuring a level of a protein selected from Apolipoprotein B and a fragment thereof; and (ii) correlating said level of protein obtained in said measuring step with the occurrence of a prion disease.

In a sixth aspect, the invention provides a method for the detection of PrP^{Sc} formation within a sample, which assay comprises (i) contacting said sample with a peptide or a protein selected from Apolipoprotein B; a fragment or a mimetic thereof; Apolipoprotein E; a fragment thereof and a mimetic thereof (ii) contacting the sample obtained from step (i) with PrP^C or PrP^C containing mixtures, such as brain homogenates, cell lysates, lipid rafts preparation; and (iii) determining the presence and/or amount of PrP^{Sc} in said sample.

In a seventh aspect, the invention provides a method for identifying a compound which modulates, preferably inhibits or antagonizes, the transition of PrP^C into PrP^{Sc} comprising: (i) contacting said sample with a peptide or a protein selected from Apolipoprotein B; a fragment or a mimetic thereof; Apolipoprotein E; a fragment thereof and a mimetic thereof (a) in the presence of said compound and (b) in the

absence of said compound; (ii) contacting the sample obtained from step (i) a and (i) b with PrP^C or PrP^C containing mixtures, such as brain homogenates, cell lysates, lipid rafts preparation; and (iii) determining the amount of PrP^{Sc} (a) in the presence of said compound and (b) in the absence of said compound.

5

In a eighth aspect, the invention provides an assay for the detection of PrP^{Sc} formation within a sample, which assay comprises (i) contacting said sample with a peptide or a protein selected from Apolipoprotein B; a fragment or a mimetic thereof; Apolipoprotein E; a fragment thereof and a mimetic thereof (ii) contacting the sample
10 obtained from step (i) with PrP^C or PrP^C containing mixtures, such as brain homogenates, cell lysates, lipid rafts preparation; and (iii) determining the presence and/or amount of PrP^{Sc} in said sample.

In a ninth aspect, the invention provides a screening assay for identifying a compound
15 which modulates, preferably inhibits or antagonizes, the transition of PrP^C into PrP^{Sc} comprising: (i) contacting said sample with a peptide or a protein selected from Apolipoprotein B; a fragment or a mimetic thereof; Apolipoprotein E; a fragment thereof and a mimetic thereof (a) in the presence of said compound and (b) in the absence of said compound; (ii) contacting the sample obtained from step (i) a and (i) b
20 with PrP^C or PrP^C containing mixtures, such as brain homogenates, cell lysates, lipid rafts preparation; and (iii) determining the amount of PrP^{Sc} (a) in the presence of said compound and (b) in the absence of said compound.

Detailed description of the invention

25 The following paragraphs provide definitions of various terms, and are intended to apply uniformly throughout the specification and claims unless an otherwise expressly set out definition provides a different definition.

The term "Gerstmann-Strassler-Scheinker Disease" abbreviated as "GSS" refers to a
30 form of inherited human prion disease. The disease occurs from an autosomal dominant disorder. Family members who inherit the mutant gene succumb to GSS.

The term "prion" shall mean a transmissible particle known to cause a group of such transmissible conformational diseases (spongiform encephalopathies) in humans and animals. The term "prion" is a contraction of the words "protein" and "infection" and the particles are comprised largely if not exclusively of PrP^{Sc} molecules.

5

"Prions" are distinct from bacteria, viruses and viroids. Known prions include those which infect animals to cause scrapie, a transmissible, degenerative disease of the nervous system of sheep and goats as well as bovine spongiform encephalopathies (BSE) or mad cow disease and feline spongiform encephalopathies of cats. Four prion
10 diseases known to affect humans are Kuru, Creutzfeldt-Jakob Disease (CJD), Gerstmann-Strassler-Scheinker Disease (GSS), and fatal familial insomnia (FFI) (*Prusiner, 1991*). As used herein prion includes all forms of prions causing all or any of these diseases or others in any animals used -- and in particular in humans and in domestic farm animals.

15

The term "lipid rafts" refers to small platforms, composed of sphingolipids and cholesterol in the outer exoplasmic layer, connected to Cholesterol in the inner cytoplasmic layer of the bilayer that have been reviewed recently (*Simons et al., 2000*). Lipid rafts can be isolated as they are insoluble in certain detergents such as triton X-
20 100 at 4°C. Therefore, rafts can be purified as detergent-insoluble membranes (DIMs) or detergent-resistant membranes (DRMs) by ultracentrifugation on sucrose gradients. Rafts are enriched in GPI-anchored proteins, as well as proteins involved in signal transduction and intracellular trafficking. In neurons, lipid rafts act as platforms for the signal transduction initiated by several classes of neurotrophic factors (*Tsui-Pierchala et al., 2002*). Example for lipid rafts extraction is given in Example n° 2 §c.
25

30

The term "prion conversion factor" refers to a factor comprising proteins, lipids, enzymes or receptors that acts as a co-factor or auxiliary factor involved in the process of conversion of PrP^C into PrP^{Sc} and favors the onset and/or progression of the prion disease.

The terms "standardized prion preparation", "prion preparation" and the like are used interchangeably herein to describe a composition containing prions which composition is obtained for example from brain tissue of mammals substantially the same genetic material as relates to PrP proteins, e.g. brain tissue from a set of mammals which exhibit
5 signs or prion disease or for example a composition which is obtained from chronically prion infected cells.

The terms "sensitive to infection", "sensitive to prion infection" and the like are use for a material from a mammal, including cells, that can be infected with an amount and type
10 of prion which would be expected to cause prion disease or symptoms.

By analogy, the terms "resistant to infection", "resistant to prion infection" and the like are used for a material from a mammal, including cells which has the characteristic to be resistant when infected with an amount and type of prion which would be expected
15 to cause prion disease or symptoms and remain uninfected even after several infective prion material inoculations.

The term "sample" refers to a biological extract from a mammal, including cell sample, body fluid, genetic material such as brain homogenate, cells, lipid rafts or purified
20 peptides and proteins.

The term "incubation time" shall mean the time from inoculation of an animal with a prion until the time when the animal first develops detectable symptoms of disease resulting from infection, it also means the time from inoculation of material from a
25 mammal, e.g. brain homogenate, cells, lipid rafts from cells, with prion until the time when the prion infection is detectable such as through the conversion of PrP^C into PrP^{Sc}. Several methods of detection of prion infection and PrP conversion are known by a person skilled in the art.

30 The terms "fraction" or "fragment" refer to any fragment of the polypeptidic chain of the compound itself, alone or in combination with related molecules or residues bound to it, for example residues of sugars or phosphates, or aggregates of the original

polypeptide or peptide. Such molecules can result also from other modifications which do not normally alter primary sequence, for example *in vivo* or *in vitro* chemical derivativization of peptides (acetylation or carboxylation), those made by modifying the pattern of phosphorylation (introduction of phosphotyrosine, phosphoserine, or phosphothreonine residues) or glycosylation (by exposing the peptide to enzymes which affect glycosylation e.g., mammalian glycosylating or deglycosylating enzymes) of a peptide during its synthesis and processing or in further processing steps.

The terms "modulator" or "modulatory compound" refer to molecules that modify the functions and/or properties (such as receptor binding, lipid affinity, enzyme interaction, structural arrangement, synthesis, metabolism) of the natural protein. "Modulators" or "modulatory compounds" include "agonists" and antagonists". Modulators" include peptides, proteins or fragments thereof, peptidomimetics, organic compounds and antibodies.

The term "mimetic" refer to molecules that mimic the functions and/or properties (such as receptor binding, lipid affinity, enzyme interaction, structural arrangement, synthesis, metabolism) of a natural protein. These compounds have for example the property to either enhance a property of the natural protein (i.e. to lead to the same activity when the compound is added to the natural protein as obtained with an increase in concentration in the natural protein) or to exhibit the same property as a natural protein (i.e. to lead to the same activity when the compound replaces the natural protein). "Mimetics" include peptides, proteins or fragments thereof, peptidomimetics and organic compounds. Examples of Apolipoprotein E mimetics are described in *US 20020128175* and *WO 2004043403*.

The terms "inhibitor" or "antagonist" refer to molecules that alter partially or impair the functions and/or properties (such as receptor binding, lipid affinity, enzyme interaction, structural arrangement, synthesis, secretion, metabolism) of the natural protein. "Inhibitors" or "antagonists" include peptides, proteins or fragments thereof, peptidomimetics, organic compounds and antibodies. Examples of Apolipoprotein B antibodies are described in *Choi et al., 1997* and in *Wang et al., 2000*. Examples of

Apolipoprotein antagonists can be antagonists that alter or impair the role of Apolipoproteins B or E in the cholesterol transport pathway. Examples of compounds that alter Apolipoprotein B secretion or synthesis are described in *US 6,369,075*, *US 6,197,972*, *WO 03/002533* and *WO 03/045921*. Other "modulators" or "antagonists" can
5 be modulators of the LDL receptor, preferably LDL-receptor antagonists such as anti-LDL receptor antibodies. Examples of monoclonal antibodies to the LDL receptor are given in *WO 01/68710*.

The term "protein misfolding cyclic amplification assay" or "PMCA assay" is an assay
10 that for the diagnosis or detection of conformational diseases which comprises a cyclic amplification system to increase the levels of the pathogenic conformer such as described for example in *WO 02/04954*.

The term "marker" for a disease refers to a biological parameter or value including a
15 genetic character, inherited protein mutation(s), blood level of a protein or an enzyme that is different from the average value in a heterogeneous population of individuals and whose occurrence correlates with the occurrence of said disease with a statistical significance. A "marker" for a disease or condition is typically defined as a certain cut-off level of a said biological variable. A "marker" provides basis for determining the
20 risk (probability of occurrence) of a disease in a subject.

The term "complex" includes the formation of an entity by the interaction of several molecules, several proteins, several peptides together or with a receptor. These interactions may be reversible and/or transient. These interactions may induce changes
25 in the properties of the interacting molecules, proteins, peptides or receptors.

By "effective amount", it is meant a concentration of peptide(s) that is capable of slowing down or inhibiting the formation of PrP^{Sc} deposits, or of dissolving preformed deposits. Such concentrations can be routinely determined by those of skill in the art. It
30 will also be appreciated by those of skill in the art that the dosage may be dependent on the stability of the administered peptide. A less stable peptide may require administration in multiple doses.

The preparation of antibodies is known by the person skilled in the art. It is referred by "antibody" to a monoclonal antibody, chimeric antibody, humanized antibody, anti-anti-Id antibody or fragment thereof which specifically recognises and binds to Apo B or Apo E and fragments thereof. For example, monoclonal antibodies are obtained through the generation of hybridoma cells lines producing monoclonal antibodies capable of specifically recognising and binding Apo B and/or fragments thereof. More specifically, these monoclonal antibodies are capable of specifically recognising and binding Apo B. A monoclonal antibody can be prepared in a conventional manner, e.g. by growing a cloned hybridoma comprising a spleen cell from a mammal immunized with hApo B and a homogenic or heterogenic lymphoid cell in liquid medium or mammalian abdomen to allow the hybridoma to produce and accumulate the monoclonal antibody. Preferably, the antibody specifically recognises and binds to Apo B-LDL recognizing fragments.

The present invention provides compounds capable of controlling, including increasing and/or inhibiting, the conversion of PrP^C into PrP^{Sc} in prion diseases.

The activity of the compounds of the invention in controlling the conversion of PrP^C into PrP^{Sc} in prion diseases can be detected using, for example, an *in vitro* assay, such as that described by *Saborio et al., 2001* which measures the ability of compounds of the invention to modulate the conversion of PrP^C into PrP^{Sc}. Results are reported in the Examples.

In one embodiment, the invention provides a use of a peptide or a protein selected from Apolipoprotein B; a fragment thereof or a mimetic thereof; Apolipoprotein E; a fragment thereof and a mimetic thereof, preferably Apolipoprotein B; a fragment thereof and a mimetic thereof; in an assay for the detection of PrP^{Sc} formation in a sample.

In one further embodiment of the invention, the peptide or the protein selected from Apolipoprotein B; a fragment thereof or a mimetic thereof; Apolipoprotein E; a

fragment thereof and a mimetic thereof, preferably Apolipoprotein B or a fragment thereof, used in an assay for the detection of PrP^{Sc} formation in a sample binds and/or forms a complex with the LDL receptor.

- 5 In another embodiment, the invention provides a use of a peptide or a protein selected from Apolipoprotein B; a fragment thereof or a mimetic thereof; Apolipoprotein E; a fragment thereof and a mimetic thereof, preferably Apolipoprotein B or a fragment thereof, in a screening assay for the identifying compounds that modulate the conversion of PrP^c into PrP^{Sc}.

10

In another further embodiment of the invention, the peptide or the protein selected from Apolipoprotein B; a fragment thereof or a mimetic; Apolipoprotein E; a fragment thereof and a mimetic thereof, preferably Apolipoprotein B or a fragment thereof, thereof, is used in a screening assay for the identifying compounds that modulate the
15 conversion of PrP^c into PrP^{Sc} binds and/or forms a complex with the LDL receptor.

In a further embodiment of the invention, the assay is a Protein Misfolding Cyclic (PMCA) assay.

- 20 In a preferred embodiment of the invention, the Protein Misfolding Cyclic (PMCA) assay uses normal brain homogenate as a source of normal PrP^c and prion conversion factor.

- 25 In a further embodiment of the invention, the protein according to the invention is Apolipoprotein B.

- In a preferred embodiment of the invention, the Protein Misfolding Cyclic (PMCA) assay uses cell lysates or lipid rafts extracted from prion infection sensitive neuroblastoma cells, such as line N2a, described in Example 2, and equivalent, as a source of normal
30 PrP^c and prion conversion factor. Lipid raft fractions can also be purified directly from the brain to serve as a source of substrate for PMCA.

In a preferred embodiment, the invention provides a use of Apolipoprotein B in an assays for the detection of PrP^C in a sample, wherein the assay is a Protein Misfolding Cyclic Amplification (PMCA) assay using lipid rafts from infection sensitive neuroblastoma cell line N2a as a source of normal PrP^C and substrate.

5

In another embodiment, the invention provides a use of a modulator, preferably an inhibitor or an antagonist, of a peptide or a protein, wherein the peptide or the protein is selected from Apolipoprotein B; a fragment thereof or a mimetic thereof for the preparation of a pharmaceutical composition for the treatment of a prion disease, notably, bovine spongiform encephalopathy (BSE) and Creutzfeldt-Jacob Disease (CJD). The modulator modifies for example the functions and/or properties of Apolipoprotein B or of a fragment thereof.

In a further embodiment of the invention, the modulator, preferably an inhibitor or an antagonist, of a peptide or a protein, wherein the peptide or the protein is selected from Apolipoprotein B; a fragment thereof and a mimetic thereof which modifies, preferably inhibits the binding and/or the formation of a complex between Apolipoprotein B and the LDL receptor. An example of such modulator can be a LDL receptor modulator, such as a LDL-receptor antagonist such as an anti-LDL receptor antibody.

20

In a preferred embodiment of the invention, the modulator is an antagonist to Apolipoprotein B or a fragment thereof.

In a further preferred embodiment of the invention, the modulator is an antibody raised against Apolipoprotein B or against a fragment thereof.

25

In another preferred embodiment of the invention, the modulator is an antibody raised against Apolipoprotein B.

In another preferred embodiment of the invention, the modulator is an antibody raised against a fragment of Apolipoprotein B, which fragment is of, or about, a molecular weight selected from 30, 35 and 40 kDa.

30

In another preferred embodiment of the invention, the modulator is an antibody raised against a fragment of Apolipoprotein B, which fragment comprises a sequence selected from fragments taken between positions 3201-3558, 3548-3905, 3201-3905, 3291-3558,
5 3548-3815 and 3291-3815.

In a preferred embodiment of the invention, the peptide or protein is selected from Apolipoprotein B or a fragment thereof.

- 10 In a preferred embodiment of the invention, the peptide or protein contains the sequence of SEQ ID NO: 3.

In another preferred embodiment of the invention, the peptide or protein is a fragment which is of, or about, a molecular weight selected from 30, 35 and 40 kDa.

15

In another preferred embodiment of the invention, the peptide or protein is a fragment of Apolipoprotein B, comprising a sequence selected from fragments, taken between positions 3201-3558, 3548-3905, 3201-3905, 3291-3558, 3548-3815 and 3291-3815.

- 20 In an embodiment of the invention, the invention provides a method for the diagnosis or detection of a prion disease within a subject suspected of suffering from such a disease which comprises (i) contacting a sample from said subject with a peptide or a protein selected from Apolipoprotein B; a fragment or a mimetic thereof; Apolipoprotein E; a fragment thereof and a mimetic thereof; preferably Apolipoprotein B or a fragment thereof, (ii) contacting the sample obtained from step (i) with PrP^C or PrP^C containing
25 mixtures, such as brain homogenates, cell lysates, lipid rafts preparation; and (iii) determining the presence and/or amount of PrP^{Sc} in said sample. The sample from the subject includes a biological extract from a mammal such as cell sample, genetic material, body fluid, brain homogenate, cells and lipid rafts.

30

In another embodiment of the invention, the invention provides a method of determining a marker that predisposes a subject to a prion disease, comprising (i)

measuring a level of a protein selected from Apolipoprotein B and a fragment thereof in said sample; (ii) contacting the sample obtained from step (i) with PrP^C or PrP^C containing mixtures, such as brain homogenates, cell lysates, lipid rafts preparation; and (iii) correlating said level of protein obtained in said measuring step with the occurrence
5 of a prion disease. The maker includes a biological parameter or value such as a genetic character, inherited protein mutation(s), blood level of a protein or an enzyme.

In another embodiment of the invention, the invention provides a method for the detection of PrP^{Sc} formation within a sample, which assay comprises (i) contacting said
10 sample with a peptide or a protein selected from Apolipoprotein B; a fragment thereof or a mimetic thereof; Apolipoprotein E, a fragment thereof and a mimetic thereof, preferably Apolipoprotein B or a fragment thereof (ii) contacting the sample obtained from step (i) with PrP^C or PrP^C containing mixtures, such as brain homogenates, cell lysates, lipid rafts preparation; and (iii) determining the presence and/or amount of PrP^{Sc}
15 in said sample. The sample can be a biological preparation for which the presence of prion is to be detected for quality control reasons and/or a sample extracted from a subject that is suspected of suffering of such a disease, including a biological extract from a mammal such as cell sample, genetic material, body fluid, brain homogenate, cells and lipid rafts.

20

In another embodiment of the invention, the invention provides a method for identifying, in a sample, a compound which modulates, preferably inhibits or antagonizes, the transition of PrP^C into PrP^{Sc} comprising: (i) contacting said sample with a peptide or a protein selected from Apolipoprotein B; a fragment thereof or a
25 mimetic thereof; Apolipoprotein E, a fragment thereof and a mimetic thereof, preferably Apolipoprotein B or a fragment thereof (ii) contacting the sample obtained from step (i) (a) in the presence of said compound and (b) in the absence of said compound; (iii) contacting the sample obtained from step (i) a and (i) b, with PrP^C or PrP^C containing mixtures, such as brain homogenates, cell lysates, lipid rafts preparation; and (iv)
30 determining the amount of PrP^{Sc} (a) in the presence of said compound and (b) in the absence of said compound. The modulator, includes antibodies, inhibitors of

Apolipoproteins B binding, including binding to the LDL receptor, and/or secretion and/or synthesis.

Still another embodiment of the present invention, is a method for treating or preventing
5 a prion disease such as bovine spongiform encephalopathy (BSE) and Creutzfeld-Jacob Disease (CJD), wherein the method comprises administering an effective dose of the above-mentioned modulator of a peptide or a protein, wherein the peptide or the protein is selected from Apolipoprotein B and a fragment thereof, to a subject in the need thereof, wherein the subject can be human or animal.

10

In a preferred method of use of the modulators, preferably inhibitors, administration of the modulators is by injection or infusion, at periodic intervals. The administration of a compound of the invention may begin before any symptoms are detected in the patient, and should continue thereafter.

15

The above-mentioned modulatory compounds of the present invention may be administered by any means that achieves the intended purpose. For example, administration may be by a number of different routes including, but not limited to subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intra-cerebral,
20 intrathecal, intranasal, oral, rectal, transdermal, intranasal or buccal. Preferably the compounds of the invention are administered by subcutaneous, intramuscular or intravenous injection or infusion.

Parenteral administration can be by bolus injection or by gradual perfusion over time. A
25 typical regimen for preventing, suppressing, or treating prion related disorders, comprises either (1) administration of an effective amount in one or two doses of a high concentration of modulatory in the range of 0.5 to 10 mg of peptide, more preferably 0.5 to 10 mg of peptide, or (2) administration of an effective amount of the peptide in multiple doses of lower concentrations of modulatory compounds in the range of 10-
30 1000 µg, more preferably 50-500 µg over a period of time up to and including several months to several years. It is understood that the dosage administered will be dependent upon the age, sex, health, and weight of the recipient, concurrent treatment, if any,

frequency of treatment, and the nature of the effect desired. The total dose required for each treatment may be administered by multiple doses or in a single dose.

Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions, which may contain auxiliary agents or excipients which are known in the art. Suitable formulations for parenteral
5 administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts. In addition, suspension of the active compound as appropriate oily injections suspensions may be administered.

10 In another embodiment of the invention is provided an assay for the detection of the formation of PrP^{Sc} within a sample, which assay comprises (i) contacting said sample with a peptide or a protein selected from Apolipoprotein B; a fragment thereof or a mimetic thereof; Apolipoprotein E, a fragment thereof and a mimetic thereof, preferably Apolipoprotein B or a fragment thereof (iii) contacting the sample obtained from step
15 (iii) contacting the sample obtained from step (ii) with PrP^C or PrP^C containing mixtures, such as brain homogenates, cell lysates, lipid rafts preparation; and (iv) determining the presence and/or amount of PrP^{Sc} in said sample. The sample can be a biological preparation for which the presence of prion is to be detected for quality control reasons and/or a sample extracted from a subject that is suspected of suffering of
20 such a disease, including a biological extract from a mammal such as cell sample, genetic material, body fluid, including blood, serum, plasma, brain homogenate, cells and lipid rafts.

In another embodiment of the invention, is provided a screening assay for identifying a
25 compound which modulates, preferably inhibits or antagonizes, the transition of PrP^C into PrP^{Sc} comprising: (i) contacting said sample with a peptide or a protein selected from Apolipoprotein B; a fragment thereof or a mimetic thereof; Apolipoprotein E; a fragment thereof or a mimetic thereof, preferably Apolipoprotein B or a fragment thereof (a) in the presence of said compound and (b) in the absence of said modulatory
30 compound; (ii) contacting the sample obtained from step (i) a and (i) b with PrP^C or PrP^C containing mixtures, such as brain homogenates, cell lysates, lipid rafts preparation; and (iii) determining the amount of PrP^{Sc} (a) in the presence of said

compound and (b) in the absence of said modulatory compound. The modulator, includes antibodies, inhibitors of Apolipoproteins B and/or secretion and/or synthesis.

5 In further embodiment of the invention, is provided a diagnostic kit for use in the assay of the invention, comprising a probe for receiving a sample and a peptide or a protein selected from Apolipoprotein B; a fragment thereof and a mimetic thereof; Apolipoprotein E, a fragment thereof and a mimetic thereof. The kit of the invention comprises kits having multi-well microtitre plate and/or multi-well sonicator.

10 In a still further embodiment of the invention, is provided an apparatus for use in the methods of the invention or in the assays of the invention. The apparatus of the invention comprises apparatus that have a microtitre plate and/or multi-well sonicator.

15 In a preferred embodiment, the prion disease is bovine spongiform encephalopathy (BSE).

In a preferred embodiment, the prion disease is sporadic, variant, familial or iatrogenic Creutzfeld-Jacob Disease (CJD).

20 The present invention has been described with reference to the specific embodiments, but the content of the description comprises all modifications and substitutions, which can be brought by a person skilled in the art without extending beyond the meaning and purpose of the claims.

25 The invention will now be described by means of the following Examples, which should not be construed as in any way limiting the present invention. The Examples will refer to the Figures specified here below.

Brief description of the drawings:

30 **Figure 1 shows *in vitro* prion replication on Hamster brain homogenate by PMCA assay in presence and absence of a cholesterol-depleting agent (Example 1§b). Samples contain 5% normal hamster brain homogenate incubated for 30 min at 4°C**

with 0, 5, 10 or 20 mM (final concentration) of methyl- β -cyclodextrin (MBCD). Aliquots of scrapie brain homogenate are added to reach a 3200- (top panel) and 12800-fold (bottom panel) dilution. Half of the samples are frozen immediately as a control without amplification (PMCA “-”) and the other half are subjected to 10 cycles of PMCA (PMCA “+”). Prion replication is evaluated by Western Blot after treatment of the samples with PK (100 μ g/ml for 60 min). The first lanes in each blot corresponds to the normal brain homogenate not treated with PK.

Figure 2 shows the effect of Apolipoproteins B, E and J *in vitro* prion replication on Hamster brain homogenate by PMCA assay (Example 1§c). Samples containing 5% normal hamster brain homogenate are incubated with different quantities of human Apolipoprotein B (2A), human Apolipoprotein E (2B) or murine Apolipoprotein J (2C) for 30 min at 4°C. Aliquots of scrapie brain homogenate are added to reach a 3200- (left panel) or 12800-fold (right panel) dilution. Half of the samples are frozen immediately as a control without amplification (PMCA “-”) and the other half are subjected to 10 cycles of PMCA (PMCA “+”). Prion replication is evaluated by western blot after treatment of the samples with PK (100 μ g/ml for 60 min). The first lanes in each blot corresponds to the normal brain homogenate not treated with PK.

Figure 3 reports differential sensitivity of N2a sub-clones to infection by Scrapie revealed by exposure to anti-PrP 6H4 mabs (Example n° 2 §b). Proteinase K (PK) exposure shows were the PrP^{Sc} isoform (Proteinase K resistant) is present. The two sub-clones highlighted #23 and #60 are chosen respectively as representatives of prion infection resistant and sensitive cells. 'N2a' shows uninfected N2a cells processed in parallel. Controls for blotting and PK digestion show 1 μ l normal or scrapie brain extract diluted in 80 μ l lysis buffer and processed in parallel.

Figure 4 shows the characterization of PrP in lipid rafts from sub-clones prion infection resistant (#23) and sensitive (#60) N2a (Example 2 §c). Figure 4A shows PrP quantification by Western blotting in lipid rafts which are extracted from prion infection resistant (#23) and sensitive (#60) cells. The distribution of PrP in the total

extract (25µg loaded) (1), the sucrose sample layer after centrifugation (25µg loaded) (2) and the bouyant lipid raft fraction (4µg loaded) (3) are presented. Figure 4B shows PrP content and glycosylation pattern of the two sub-clones #23 and #60 by Western blotting with anti-PrP. Three independent preparations of lipid rafts prion infection resistant (#23) and sensitive (#60) cells were analysed. Equal amounts (4µg) of rafts proteins were analysed in each case. Figure 4C shows the same membrane after stripping and re-probing with anti-actin which confirms the similarity in protein loading.

Figure 5 presents the *in vitro* conversion activity of lipid rafts from sub-clones prion infection resistant (#23) and sensitive (#60) N2a using PMCA (Example 2 §d). *Upper panel:* Lipid rafts are isolated from prion infection resistant (#23) and sensitive (#60) cells. Preparations are mixed in a ratio 100:1 with 10% RML brain homogenate and aliquots are frozen immediately, incubated for 15h at 37 °C or subjected to 15 cycles of PMCA. Lanes 1: initial mixture without PK digestion; lanes 2: initial mixture digested 10ug/ml PK 1hr 37 °C; lanes 3: mixture incubated 37 °C PK digested as in lane 2; lanes 4: 15 cycles of PMCA followed by PK digestion as in lane 2. Lane 5 shows the migration and cross-reactivity with anti-PrP of PK alone. *Lower panel:* Following western blotting the membrane is stained with Coomassie blue to confirm that digestion with PK was complete.

Figure 6 shows the inhibitory effect on Prion replication in prion infection sensitive cells induced by Anti-hApoB polyclonal antibody (Example 2 §e).

Chronically infected #60 sensitive cells were cultured in 24 well culture dishes in the presence of increasing amounts (0-2mg/ml) of a goat polyclonal antibody against human ApoB (Chemicon) or against a corresponding series of naïve goat IgG. The level of PrP replication was determined by quantitative dot blotting and expressed as chemiluminescent intensity/mg protein. In the graph, for each antibody concentration the chemiluminescent intensity is expressed as a percentage of the value obtained without the antibody. Higher concentrations of anti-hApoB antibody have an inhibitory effect on PrP replication.

Figure 7 shows 2D separations of lipid raft proteins from N2a cells (Example 3). Lipid rafts are isolated from prion infection sensitive cells (#60) and 2 aliquots of 25 µg are precipitated with acetone and processed for 2D analysis min the 1st dimension spanning pH ranges 3-10 (7A) or 6-11 (7B). After SDS-PAGE separation in the second dimension, gels are stained using the silver express kit (Invitrogen). Arrow indicates the same protein on both gels (7A and 7B). Proteins within the rectangle shown in B are compared between lipid raft from the prion infection sensitive sub-clone #60, (C) and resistant subclone #23, (D). Arrows indicate proteins which are more abundant in resistant cells.

Abbreviations:

Apo B (Apolipoprotein B); Apo E (apolipoprotein E); Apo J (Apolipoprotein J); BCA (Bicinchoninic Acid); CHAPS (3-((3-cholamidopropyl)dimethylammonio)-1-propanesulfonate); CNS (central nervous system); BSE (bovine spongiform encephalopathy); CJD (Creutzfeldt-Jakob Disease); DiI (1,1-dioctadecyl-3,3,3,3 - tetramethylindocarbocyanine perchlorate); DIM (Detergent-Insoluble Membrane); DMEM (Dulbecco's Modified Eagle Medium); DRM (Detergent-Resistant Membrane); DTT (1,4-Dithio-D,L-threitol); IPG (Immobilized PH Gradient); IEF (Isoelectric Focusing); FCS (Fetal Calf Serum); FFI (Fatal Familial Insomnia); GSS (Gerstmann-Strassler-Scheinker Disease); hr (hour); HRP (Horseradish Peroxidase); kDa (KiloDalton); LDL (Low Density Lipoprotein); µg (microgram); µl (microliter); min (minute); MβCD (methyl-β-cyclodextrin); mM (millimolar); MS (mass spectrometry); PBS (Phosphate Buffered Sulfate); PK (proteinase K); PMCA (Protein Misfolding Cyclic Amplification); PMSF (Phenylmethanesulfonyl Fluoride); PrP (prion protein); PrP^C (normal, non-pathogenic conformer of PrP); PrP^{Sc} (pathogenic or "scrapie" isoform of PrP which is also the marker for prion diseases); PVDF (polyvinylidene difluoride); RPM (Rotation per minute); RML (Rocky Mountain Laboratory); RT-PCR (reverse transcriptase polymerase chain reaction); SDS (Sodium Dodecyl Sulfate); V (Volt); Vol (volume).

EXAMPLES

The invention will be illustrated by means of the following examples which are not to be construed as limiting the scope of the invention.

The following examples illustrate preferred compounds and methods for determining their biological activities.

PrP scrapie used as infection inoculum is RML (Rocky Mountain Laboratory) strain.

Anti-PrP 6H4 monoclonal antibodies were purchased from Prionics.

Proteinase K was obtained from Boehringer Ingelheim and Methyl- β -cyclodextrin from Sigma.

Purified and delipidated human Apolipoprotein B (Apo B) and Apolipoprotein E (Apo E) were obtained from Chemicon.

Anti-apo B and anti-apo E are goat polyclonal antibodies against human Apo B and human Apo E, respectively obtained from Chemicon and dialysed against PBS to eliminate sodium azide.

Total goat IgG was purchased from Pierce and dialyzed against PBS.

Mouse neuroblastoma N2a cell line was obtained from ATCC.

Murine Apo J (Apo J) was obtained in-house as described in PCT/EP2004/05037.

DiI labeled LDL was obtained from Molecular Probes (L-3482).

EXAMPLE 1: *In vitro* prion replication in brain homogenate through PMCA assay:

The influence of cholesterol and some of the apolipoproteins on prion replication in vitro is analysed through a Protein Misfolding Cyclic Amplification assay (PMCA) (Saborio *et al.*, 2001) where hamster brain homogenate is used as a source of PrP^C and conversion factors as follows.

a) Brain preparation:

Brains from healthy Syrian golden hamsters healthy or infected with the adapted scrapie strain 263 K are obtained after decapitation and immediately frozen in dry ice and kept at -80° until used. Brains are homogenized in PBS containing protease inhibitors (Complete™ cocktail from Boehringer Mannheim) at a 1x final concentration. Detergents (0.5% Triton X-100, 0.05% SDS, final concentrations) are

added and samples clarified with low speed centrifugation (10000 g) for 1 min, using an Eppendorf centrifuge (model 5415).

Dilutions (3200-fold and 12800-fold) of the scrapie brain homogenate are added directly to the healthy brain homogenate to trigger prion replication. 60µl of these mixtures are frozen immediately and another 60µl are incubated at 37°C with agitation. Each hour a cycle of sonication (5 pulses of 1sec each) is done using a microsonicator (Bandelin Electronic, model Sonopuls) with the probe immersed in the sample and the power setting fixed at 40%. These cycles are repeated 10 times.

b) PMCA signal in presence and absence of a cholesterol-depleting agent:

Under these conditions a dramatic increase in the amount of PrP^{Sc} signal is observed after 10 cycles of PMCA (Figure 1, lanes 2 and 3). When normal brain homogenate is treated during 30 min with 10 and 20mM (but not 5 mM) methyl-β-cyclodextrin (MBCD) a complete inhibition of prion replication is observed (Figure 1, lanes 6-9) as obtained in mouse models in cell cultures and in vitro, indicating that cholesterol depletion has a detrimental effect on prion replication (*Taraboulos et al., 1995*).

c) PMCA signal in presence of apolipoproteins

Purified delipidated human ApoB (Figure 2A) and human Apo E (Figure 2B) are respectively added to the PMCA preparation without cyclodextrin at different concentrations (8 and 16 µg for hApo B) and (1 and 10 µg for hApo E). Samples are incubated for 30 min at 4°C and thereafter half of each sample is frozen and the other half subjected to PMCA cycles.

An increase in prion replication in vitro is observed at both 3200-fold and 12800-fold dilutions of scrapie brain homogenate for both Apolipoprotein B and Apolipoprotein E.

In contrast, addition of Apolipoprotein J (at concentrations of 1, 2 and 4 µg), an Apolipoprotein component of HDL, has no effect on PMCA signal (Figure 2C).

These data show the effect of Apolipoprotein B and E implicated in the prion conversion.

EXAMPLE 2: *In vitro* prion replication in lipid rafts from prion infection sensitive cells by PMCA:

The mouse neuroblastoma cell line N2a is used for their capability to be infected with PrP^{Sc}. Baron et al., 2002 and Enari et al., 2001 have shown that prion infection sensitive and prion infection resistant N2a sub-lines exist. Lipid rafts from the prion infection sensitive line are isolated and used as a substrate for PMCA assay. The effect of an apolipoprotein B antagonist on prion conversion is studied through the ability of apolipoprotein B antagonist to inhibit the prion replication ability of prion infection sensitive N2a cell lines.

a) N2a cell preparation:

Sub-clones of the parental mouse neuroblastoma N2a cell line are derived from single cells by limit dilution. A growing culture (Dulbecco's Modified Eagles Medium (DMEM Gibco # 41966-029), containing 10% fetal calf serum (FCS) and supplemented with 2mM, L-glutamate and standard antibiotics (penicillin and streptomycin)) is diluted to a density of 5 cells/ml and 100µl is transferred to individual wells of a 96 well plate and cultured for 1 week.

The individual cultures are examined microscopically to determine those wells which contained a single focus of growing cells. The single cell derived cultures are then transferred to 24 well plates and serially passaged every 3-4 days at 1:15 dilution to maintain stocks. A total of 63 cultures are isolated and all tested for sensitivity to infection by the RML strain of PrP^{Sc}. To do this, 4µl of a 10% late stage infected brain extract is added per well of newly passaged cells, and the cultures are left for a further 4 days to reach 100 % confluence. Cells were serially passaged thereafter in the absence of PrP^{Sc}. Tests showed that all trace of the initial inoculum disappeared by passage 4.

At this and later passages individual cultures are tested for the presence of PrP^{Sc}.

b) Prion infection resistant cell isolation by Cell culture dot blotting:

The presence of PrP^{Sc} in the 63 individual cell cultures is tested by cell culture dot blotting procedure in which lysis and proteinase K (PK) digestion are carried out directly in the culture dish. PK resistant PrP^{Sc} is detected by dot blotting to PVDF membranes and exposure to anti-PrP antibody as follows:

Infected cells are grown for 3-4 days in 24-well plates and washed once with PBS. 40µl DNaseI (1000U/ml in H₂O) is added to each well at room temperature for 5min, followed by 40µl proteinase K solution (20µg/ml in 100mMTris/HCl pH 7.4, 300mM NaCl, 1% Triton-X100, 1% sodium deoxycholate). Plates are incubated at 37°C
5 for 1hr with gentle agitation. Proteinase K digestion is stopped by addition of 2µl of a solution containing 80µg/ml PMSF, 10mMTris-HCl pH 8.0 and 1mg/ml bromophenol blue. 20µl aliquots are spotted onto PVDF membranes equilibrated with a degasses solution containing 192mM Glycine, 25mM Tris, 20% methanol. Membranes are then transferred to 3M guanidine Thiocyanate, 10mM Tris HCL pH 8.0 for 10min to
10 denature proteins, rinsed in water and processed as for Western blotting using anti-PrP 6H4 (Prionics). Non-specific binding is blocked by incubation with 5% milk dissolved in PBS for 1hr. The membrane is then exposed to specific primary antibody anti-PrP 6H4, followed by HRP-conjugated secondary antibody each diluted as appropriate in PBS, 0.3% Tween 20. Western blots are developed by ECL™ (Amersham) as directed
15 according to the provider instructions.

The chemiluminescence signal from membranes is then analyzed directly using the Kodak Imagestation 440CF. The luminescence signal in each condition was normalized for possible differences in cell growth. Total protein content of a parallel lysate untreated with proteinase K is determined using the BCA assay (Biorad) and
20 results are expressed as intensity/µg protein.

Of the 63 sub-clones analysed, 9 were found to be capable of replicating PrP^{Sc}, albeit with differing efficiencies (Figure 3). The remaining 54 sub-clones were resistant to infection. The most highly prion infection sensitive cell lines were selected for further study together with several prion infection resistant sub-clones with similar
25 morphologies and doubling times. We have have selected two of these cell lines: #23, a prion infection resistant clone, and #60 a prion infection sensitive clone.

These two cell lines have been maintained in culture for over 1 year and have been infected with RML in many different occasions throughout this period: on every occasion sub-clone #60 was highly infectable whereas sub-clone #23 was totally
30 resistant. Prion infection sensitive sub-clones could be maintained as a chronically infected cell culture by serial passaging at 1:15 or 1:20 dilution every 3 or 4 days respectively.

No evident morphological differences by microscopy were observed between the resistant or sensitive cells or between non-infected and infected cells.

To validate the clinical relevance of this cellular model of PrP replication, extracts of chronically infected N2a cells, or buffer alone, were injected into the hippocampus of normal mice by stereotactic injection. Injection of N2a extracts resulted in onset of clinical symptoms of scrapie after 140 days and premature death whereas mock injection had no effect on mouse physiology or life span. This indicates that the cell based model for prion replication using prion infection sensitive N2a cells generates infectious PrP scrapie, confirming that the conversion of PrP in cells is a good model for the process which occurs in vivo.

c) Lipid rafts isolation:

Procedures for isolating lipid rafts based on resistance to solubilization in cold Triton X-100 followed by flotation on sucrose gradients have been described by numerous laboratories (*Simons et al., 2000; Hooper et al., 1999*). Lipid rafts from the two cell lines selected above are carried out as follows:

Subconfluent cultures of N2a cells are washed in PBS and collected by centrifugation 1000 x g for 5min. Typically 3 x 15cm dishes are pooled equivalent to approximately 8×10^7 cells. The cell pellet is re-suspended in 1ml ice cold raft buffer (1% Triton in PBS, containing 10 μ M copper sulphate and a cocktail of complete protease inhibitors (Boehringer)). Cells are disrupted by seven passages through a 22G needle followed by incubation for 30 min at 4°C with gentle agitation. 2 volumes 60% sucrose in PBS is added and the lysate is transferred to a SW41 centrifuge tube. The lysate is carefully overlaid with 7 ml 35% sucrose and 1ml 15% sucrose both in PBS and centrifuged 20hr at 35,000 RPM. The lipid rafts are recovered in the top 1ml of the gradient. Membranes are concentrated by addition of 10 volumes cold PBS and centrifugation at 100,000g for 2hr. Alternatively for 2D gel electrophoresis, proteins from the lipid raft fraction are recovered by precipitation in the presence of 5 vol acetone for 2hr at -80°C. Acetone precipitates are collected by centrifugation 14000g 20min and washed twice in 70% ethanol.

In both sensitive and resistant cells around 1-2% of protein in the total lysate is recovered in the bouyant raft fraction. As shown by Western blotting (Figure 4A) while PrP is barely detectable in the total cell extract, it is highly enriched in rafts leaving the sample layer totally depleted of PrP following centrifugation.

5 Prion infection sensitive clone #60 and the prion infection resistant clone #23 are compared by western blotting with anti-PrP (Figure 4B). Three different independent pairs of raft preparations each containing 5µg total raft proteins are re-probed with anti-actin antibody which confirms the uniformity of PrP protein loading (Figure 4C).

10 The results indicate that the level of PrP in the lipid raft preparations from the two cell types is indistinguishable. Moreover the distribution between non-glycosylated mono- and di-glycosylated isoforms as well as the segregation to the detergent resistant membrane fraction shown in Figure 4A is identical suggesting that none of these factors are likely to be responsible for the differing phenotypes.

15 PrP cDNA was amplified by RT-PCR from both cell lines as follows:
Total RNA of N2a cells is prepared using Trizol (Gibco) and the mouse PrP cDNA is reversed transcribed with Omniscript (Qiagen) using the protocol supplied by the manufacturer. The specific primer for cDNA synthesis is 5'
20 TCAATTGAAAGAGCTACAGGTG 3'. The prion cDNA is amplified using standard PCR conditions in the presence of primers 5' ACCAGTCCAATTTAGGAGAGCC 3' (top strand) and 5' AGACCACGAGAATGCGAAGG 3' (bottom strand). The PCR product was completely sequenced in the automated ABI3700 using the reagents and the protocol supplied by the manufacturer.

25 These data revealed that PrP mRNA is wild type in both cases and that both carry a Methionine at position 129, which in humans is the site for a frequent polymorphism.

Therefore, the expression levels, glycosylation patterns, intracellular localisation and primary sequences of PrP^C in both cell types is indistinguishable and thus that other
30 cellular factors are responsible for the differential response to PrP^{Sc}.

d) *In vitro* cyclic amplification of protein misfolding (PMCA) in lipid rafts from prion infection sensitive cells:

Lipid rafts obtained at §c are isolated from prion infection sensitive sub-clones, #60 sub-clones, collected by centrifugation as described above and re-suspended in PMCA conversion buffer at a concentration of 2-2.5 mg/ml (PBS containing final concentration of 300mM NaCl, 0.5% Triton X100, 0.05% SDS).

A 10% extract of RML-infected mouse brain homogenate is added directly to the rafts preparation at a dilution of 1:100 based on protein content and aliquots of the mixture are either frozen immediately, incubated for 15hr at 37°C or subjected to 15 cycles of PMCA (5 x 0.1 second pulses of sonication followed by incubation at 37 °C for 1hr).

Aliquots of 20µl sample are then treated with 10 µg /ml Proteinase K for 1hr at 37°C. Lipids are removed by precipitating PK-resistant proteins with 5 vol acetone for 2hr at -80°C. Acetone precipitates are collected by centrifugation 14000g 20 min, washed twice in 70% ethanol analysed by Western blotting with 6H4 anti-PrP (Figure 5).

Compared to the mixture without PK treatment (lanes 1 and 5) all digested samples show a shift in molecular weight characteristic of the N-terminally truncated PK resistant form PrP₂₇₋₃₀. It should be noted that the 6H4 antibody also has low level cross reactivity with PK which migrates at 30kDa, close to the di-glycosylated form of PK-digested PrP. Analysis of the data with this in mind shows that the initial level of PK-resistant PrP derived from the diluted brain extract, which is present in the non-amplified mixtures, is barely detectable under these conditions (lanes 2).

A slight increase in signal is seen when the prion infection sensitive (#60) DRM is incubated at 37 °C for 15 hr (lane 3 from #60), however the most dramatic increase in PK-resistant PrP is seen when this sample is subjected to 15 cycles of PMCA (lane 4 from #60). This indicates that all factors required for conversion of PrP^C to PrP^{Sc} are resident in the lipid rafts from the prion infection sensitive N2a cells. Interestingly, in the parallel analysis in which the DRM from the prion infection resistant cell line #23 was used, no amplification in vitro was observed (lane 4 from #23) indicating that the capacity of the lipid rafts to convert the prion protein in vitro reflects the activity observed in the intact cells.

e) Effect of antibody raised against apolipoprotein B on prion replication by prion infection sensitive N2a cells:

Chronically infected sensitive cells were cultured in 24-well dishes in the presence of a goat polyclonal antibody raised against human Apo B (Chemicon) at increasing concentrations from 0 to 2 mg/ml in DMEM Gibco # 41966-029, containing 1 x B27 supplements (Gibco #17504-044) and standard antibiotics (penicillin and streptomycin)

A parallel series of cultures was incubated in the presence of the same concentration range of total IgG from a naïve goat. The results show that concentrations of anti-hApoB antibody above 0.5mg/ml result in progressive inhibition of PrP replication as revealed by quantitative dot blotting (Figure 6).

These data show the role of Apolipoprotein B in the prion conversion.

EXAMPLE 3: Proteomics analysis of lipid rafts of prion infection resistant and sensitive cells:

Since the two cell preparations are indistinguishable in terms of their PrP content a more complete protein comparison using 2D gel electrophoresis was performed to show differences in other proteins that might underline the difference in conversion activity between the two sub-clones.

2D gel preparations are prepared as follows:

Acetone precipitated proteins (see §c) are re-suspended in 20µl 1% SDS, 0.23% DTT and heated to 95°C for 5min. After the preparation is cooled to room temperature, 25µl of a solution (9M urea, 4% CHAPS, 65mM DTT, 35mM Tris base) is added.

Fifteen minutes later, 85µl of a solution containing 7M urea, 2M thiourea, 4% CHAPS, 100mM DTT is further added to the mixture. After a further 15 min, non-solubilized material is removed by centrifugation at 14000 RPM during 5min and the supernatant is applied directly to a 7cm IPG strip and left to re-hydrate overnight. For IEF the voltage is progressively increased from 300V to 3.5kV and electrophoresed for a total of 20kVh. Proteins are resolved in the second dimension using single well 4-12% gradient gels (Novex) and stained using the silver express kit (Invitrogen) according to the instructions supplied.

Analysis by 2D gels reveals the fraction of protein that is recovered in the lipid rafts (approximately 1-2% protein in the N2a cell lysate) as a reproducible subset of total cell proteins in which several hundred species can be visualized following silver staining (Figure 7A and B).

5 The 2D patterns are compared between preparations isolated from the prion infection sensitive and resistant cells. The analysis is focused on several proteins identified in the basic range of the gel, which are more abundant in DRMs from prion infection resistant cells (arrows in Figure 7C and D).

10 Following preparative scale electrophoresis, the two proteins indicated by arrows are excised and processed for MS sequencing. From both proteins an identical tryptic peptide is found with a monoisotopic mass of 1234.6. The N-terminal sequence of this tryptic peptide is: ENFAGEATLQR (SEQ ID NO: 3). All amino acids in the peptide are identified in the MS/MS spectrum of doubly charged precursor ion at m/z 618.30 And through its Mascot analysis.

15 Database searching identified this protein unambiguously as Apolipoprotein B (Apo B). Since the molecular weight of full length Apo B is in excess of 500 kDa while these two spots migrate with estimated molecular weights of 40kDa and 30kDa, we presume that the latter are fragments generated either in the cell or during sample preparation. The sequence corresponds to amino acids 3548-3558 of the human Apo B protein, which is present only in ApoB-100 and not in the truncated ApoB-48 form.

20 These data suggest that fragments of a molecular weight of or about 30 to 40 kDa comprising the sequence of SEQ ID NO: 3 may have a role in the prion conversion pathway.

25 **EXAMPLE 4: Binding and internalisation of fluorescent LDL receptor by resistant and sensitive cells:**

 N2a subclones #23 (prion infection sensitive) and #60 (prion infection resistant) were cultured in 24 well plates in standard DMEM medium containing 10% FCS for 2 days then transferred to the same medium (300 µl) containing 1% FCS for 1hr. To visualize
30 cell surface binding, plates were placed on ice to inhibit endocytosis and 3µl fluorescent DiI-LDL (Molecular Probes) was added for 30 min.

LDL-binding was visualized by fluorescence microscopy. To study LDL uptake by each of the sub-clones, cells were incubated at 37 C with 3 μ l DiI-LDL for 2h prior to microscopic examination.

Control cultures were incubated in parallel with DiI-coupled *acetylated* LDL which
5 does not bind the LDL receptor or with Hoechst to visualize cell nuclei.

The binding or uptake of fluorescent DiI-LDL is similar for prion infection resistant and prion infection sensitive cells, suggesting that the level of the LDL receptor between these two cell types is similar.

References

- Aizawa et al., *Brain R.* 768 (1-2), 208-14, 1997;
Baron et al., *The EMBO Journal*, 21, 5, 1031-1040, 2002;
5 Baumann et al., *Biochem J.*, 349, 77-8, 2000;
Bruce et al., *Nature*, 389, 498-501, 1997;
Bueler et al., *Cell* 73, 1339-1347, 1993;
Chabry et al., *J. Biol. Chem.* 273, 13203-13207, 1998;
Choe et al., *Electrophoresis*, 23, 2242-2246, 2002;
10 Choi et al., *J. Lip. Res.*, 38(1)77-85, 1997;
Clavey et al., *Annales d'Endocrinologie*, 52, 459-463, 1991;
Cohen et al., *Ann. Rev. Biochem.* 67, 793-819, 1998;
Dietrich et al., *Journal of virology*, 65(9), 4759-476, 1991;
Enari et al., *Proc. Natl. Acad. Sci. USA* 98, 9295-9299, 2001;
15 Fantini et al., *Expert Reviews in Molecular Medicine*, Dec 20, 1-22, 2002;
Golaz et al., *Electrophoresis*, 16, 1184-118, 1995;
Hooper et al., *Mol. Memb. Biol.* 16, 145-156, 1999;
Lehninger et al., *Principles of Biochemistry*, 2nd Ed. New York: Worth Publishers, 1993;
20 Lucassen et al., *Biochemistry*, 42, 4127-4135, 2003;
Pan et al., *Proc. Natl. Acad. Sci. (USA)* 90, 10962-10966, 1993;
Prusiner, *Science* 252, 1515-1522, 1991;
Prusiner, *Proc. Natl. Acad. Sci. USA* 95, 13363-13383, 1998;
Roos et al., *Brain* 96, 1-20, 1973;
25 Saborio et al., *Biochem. Biophys. Res. Commun.* 258, 470-475, 1999;
Saborio et al., *Nature* 411, 810-813, 2001;
Schulz et al., *American Journal of Pathology*, 156(1), 51-56, 2000;
Segrest et al., *Journal of Lipid Research*, 42, 1346-1367, 2001;
Simons et al., *Molecular Cell Biology* 1, p 31-41, 2000;
30 Scott et al., *Proc. Natl. Acad. Sci. USA* 96, 15137-15142, 1999;
Soto et al., *Trends Mol. Med.* 7, 109-114, 2001;
Taraboulos et al., *The Journal of Cell Biology*, 129 (1), 121-132, 1995;

- Telling et al., Proc. Natl. Acad. Sci. USA 91, 9936-9940, 1994;
Tsui-Pierchala et al., Trends Neurosci. 25, 412-417, 2002;
Wang et al., Atheroscler. Thromb. Vas. Biol., 20(5), 1301-8, 2000;
Will et al., Lancet 347, 925, 1996;
5 Yamada et al, Ann Clin. Lab. Sci. 27(4), 77-85, 1997;
US 5,134,121;
US 5,276,059;
US 5,948,763;
US 6,022,683;
10 US 6,197,972;
US 6,355,610;
US 6,552,922;
US 20020128175;
US 20020155426;
15 WO 97/14437;
WO 99/15159;
WO 0168710;
WO 0204954;
WO 02065133;
20 WO 03002533;
WO 03005037;
WO 03045921;
WO 2004043403.

Claims

1. Use of a peptide or a protein selected from Apolipoprotein B; a fragment thereof; Apolipoprotein E and a fragment thereof, in an assay for the detection of the formation of PrP^{sc} in a sample.
5
2. Use of a peptide or a protein selected from Apolipoprotein B; a fragment thereof; Apolipoprotein E and a fragment thereof, in a screening assay for identifying compounds that modulate the conversion of PrP^C into PrP^{sc}.
10
3. Use according to claims 1 or 2 wherein the peptide or protein is selected from Apolipoprotein B; a fragment thereof; Apolipoprotein E and a fragment thereof, which forms a complex with the LDL receptor.
- 15 4. Use according to any of the preceding claims wherein the assay is a Protein Misfolding Cyclic Amplification (PMCA) assay.
5. Use according to any of the preceding claims wherein the assay is a Protein Misfolding Cyclic Amplification (PMCA) assay using normal brain homogenate as a source of normal PrP^C and substrate.
20
6. Use according to claims 1 to 4 wherein the assay is a Protein Misfolding Cyclic Amplification (PMCA) assay using lipid rafts from infection sensitive neuroblastoma cell line N2a as a source of normal PrP^C and substrate.
25
7. Use according to any of the preceding claims wherein the protein is Apolipoprotein B.
8. Use according to any of the preceding claims wherein the protein is Apolipoprotein B, the assay is a Protein Misfolding Cyclic Amplification (PMCA) assay using lipid rafts from infection sensitive neuroblastoma cell line N2a as a source of normal PrP^C and substrate.
30

- 5 9. Use of a modulator of a protein or a peptide, wherein the protein is selected from from Apolipoprotein B and a fragment thereof, for the preparation of a pharmaceutical composition for the treatment of a prion disease.
- 10 10. Use according to claim 9 wherein the modulator is an antibody raised against Apolipoprotein B or a fragment thereof.
11. Use according to any of the preceding claims wherein the peptide or the protein
10 contains the sequence of SEQ ID NO: 3.
12. Use according to any of the preceding claims wherein the peptide or the protein
is of a molecular weight selected from 30 and 40 kDa and which sequence is
selected from fragments of Apolipoprotein B taken between positions 3201-
15 3558, 3548-3905, 3201-3905, 3291-3558, 3548-3815 and 3291-3815.
13. Use according to any one of claims 9 to 12 wherein the prion disease is bovine
spongiform encephalopathy (BSE).
- 20 14. Use according to any one of claims 9 to 12 wherein the prion disease is a Creutzfeld-Jacob Disease (CJD).
- 25 15. A method for the diagnosis or detection of a prion disease within a subject suspected of suffering from such a disease which comprises (i) contacting a sample from said subject with a peptide or a protein selected from Apolipoprotein B; a fragment thereof; Apolipoprotein E and a fragment thereof; (ii) contacting the mixture obtained in step (i) with PrP^C or PrP^C containing mixtures; and (iii) determining the presence and/or amount of PrP^{Sc} in said sample.
- 30 16. A method of determining a marker that predisposes a subject to a prion disease, comprising (i) measuring a level of a protein selected from Apolipoprotein B; a

fragment thereof; in said sample; and (ii) correlating said level of protein obtained in said measuring step with the occurrence of a prion disease.

- 5 17. A method according to any one of claims 15 to 16 wherein the prion disease is bovine spongiform encephalopathy (BSE).
18. A method according to any one of claims 15 to 16 wherein the prion disease is a Creutzfeld-Jacob disease.
- 10 19. A method for the detection of PrP^{Sc} within a sample, which assay comprises (i) contacting said sample with a peptide or a protein selected from Apolipoprotein B; a fragment thereof; Apolipoprotein E and a fragment thereof; (ii) contacting sample obtained in (i) with PrP^C or PrP^C containing mixtures; and (iii) determining the presence and/or amount of PrP^{Sc} in said sample.
- 15 20. A method for identifying, in a sample, a compound which modulates the transition of PrP^C into PrP^{Sc} comprising: (i) contacting said sample with a peptide or a protein selected from Apolipoprotein B; a fragment thereof; Apolipoprotein E and a fragment thereof; (a) in the presence of said modulatory compound and (b) in the absence of said compound; (ii) contacting the mixtures obtained in step (i) a and (i) b with PrP^C or PrP^C containing mixtures; and (iii) determining the amount of PrP^{Sc} (a) in the presence of said modulatory compound and (b) in the absence of said modulatory compound.
- 20 21. A method according to any one of claims 15 to 20 wherein the peptide or the protein contains the sequence of SEQ ID NO: 3.
- 25 22. A method according to any one of claims 15 to 21 wherein the peptide or the protein is of a molecular weight selected from 30 and 40 kDa and which sequence is selected from fragments of Apolipoprotein B taken between positions 3201-3558, 3548-3905, 3201-3905, 3291-3558, 3548-3815 and 3291-3815.
- 30

23. An assay for the detection of PrP^{Sc} in a sample, which assay comprises (i) contacting said sample with a peptide or a protein selected from Apolipoprotein B; a fragment thereof; Apolipoprotein E and a fragment thereof; (ii) contacting
5 the mixture obtained in step (i) with PrP^C or PrP^C containing mixtures; (iii) determining the presence and/or amount of PrP^{Sc} in said sample.
24. A screening assay for identifying a compound which modulates the transition of PrP^C into PrP^{Sc} comprising: (i) contacting said sample with a peptide or a protein
10 selected from Apolipoprotein B; a fragment thereof; Apolipoprotein E and a fragment thereof; (a) in the presence of said modulatory compound and (b) in the absence of said modulatory compound; (ii) contacting the mixtures obtained in step (i) a and (i) b with PrP^C or PrP^C containing mixtures; and (iii) determining the amount of PrP^{Sc} (a) in the presence of said compound and (b) in
15 the absence of said modulatory compound.
25. An assay according to any one of claims 23 to 24 wherein the peptide or the protein contains the sequence of SEQ ID NO: 3.
- 20 26. An assay according to any one of claims 23 to 25 wherein the peptide or the protein is of a molecular weight selected from 30 and 40 kDa and which sequence is selected from fragments of Apolipoprotein B taken between positions 3201-3558, 3548-3905, 3201-3905, 3291-3558, 3548-3815 and 3291-3815.
- 25 27. A diagnostic kit for use in an assay according to claims 23 to 26, comprising a probe for receiving a sample and a peptide or a protein selected from Apolipoprotein B and a fragment thereof.
- 30 28. An apparatus for use in a method according to any one of claims 15 to 22 or an assay according to any one claims 23 to 26.

Figure 1




Figure 2A




Figure 2B




Figure 2C




Figure 3




Figure 4




Figure 5






Figure 6





SEQUENCE LISTING

<110> APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

<120> USE OF PRION CONVERSION MODULATING AGENTS

<130> WO/845

<160> 3

<170> PatentIn version 3.1

<210> 1

<211> 4563

<212> PRT

<213> Homo sapiens

<400> 1

Met Asp Pro Pro Arg Pro Ala Leu Leu Ala Leu Leu Ala Leu Pro Ala
 1 5 10 15

Leu Leu Leu Leu Leu Leu Ala Gly Ala Arg Ala Glu Glu Glu Met Leu
 20 25 30

Glu Asn Val Ser Leu Val Cys Pro Lys Asp Ala Thr Arg Phe Lys His
 35 40 45

Leu Arg Lys Tyr Thr Tyr Asn Tyr Glu Ala Glu Ser Ser Ser Gly Val
 50 55 60

Pro Gly Thr Ala Asp Ser Arg Ser Ala Thr Arg Ile Asn Cys Lys Val
 65 70 75 80

Glu Leu Glu Val Pro Gln Leu Cys Ser Phe Ile Leu Lys Thr Ser Gln
 85 90 95

Cys Thr Leu Lys Glu Val Tyr Gly Phe Asn Pro Glu Gly Lys Ala Leu
 100 105 110

Leu Lys Lys Thr Lys Asn Ser Glu Glu Phe Ala Ala Ala Met Ser Arg
 115 120 125

Tyr Glu Leu Lys Leu Ala Ile Pro Glu Gly Lys Gln Val Phe Leu Tyr
 130 135 140

Pro Glu Lys Asp Glu Pro Thr Tyr Ile Leu Asn Ile Lys Arg Gly Ile
 145 150 155 160

Ile Ser Ala Leu Leu Val Pro Pro Glu Thr Glu Glu Ala Lys Gln Val

165	170	175
Leu Phe Leu Asp Thr Val Tyr Gly Asn Cys Ser Thr His Phe Thr Val		
180	185	190
Lys Thr Arg Lys Gly Asn Val Ala Thr Glu Ile Ser Thr Glu Arg Asp		
195	200	205
Leu Gly Gln Cys Asp Arg Phe Lys Pro Ile Arg Thr Gly Ile Ser Pro		
210	215	220
Leu Ala Leu Ile Lys Gly Met Thr Arg Pro Leu Ser Thr Leu Ile Ser		
225	230	235
Ser Ser Gln Ser Cys Gln Tyr Thr Leu Asp Ala Lys Arg Lys His Val		
245	250	255
Ala Glu Ala Ile Cys Lys Glu Gln His Leu Phe Leu Pro Phe Ser Tyr		
260	265	270
Asn Asn Lys Tyr Gly Met Val Ala Gln Val Thr Gln Thr Leu Lys Leu		
275	280	285
Glu Asp Thr Pro Lys Ile Asn Ser Arg Phe Phe Gly Glu Gly Thr Lys		
290	295	300
Lys Met Gly Leu Ala Phe Glu Ser Thr Lys Ser Thr Ser Pro Pro Lys		
305	310	315
Gln Ala Glu Ala Val Leu Lys Thr Leu Gln Glu Leu Lys Lys Leu Thr		
325	330	335
Ile Ser Glu Gln Asn Ile Gln Arg Ala Asn Leu Phe Asn Lys Leu Val		
340	345	350
Thr Glu Leu Arg Gly Leu Ser Asp Glu Ala Val Thr Ser Leu Leu Pro		
355	360	365
Gln Leu Ile Glu Val Ser Ser Pro Ile Thr Leu Gln Ala Leu Val Gln		
370	375	380
Cys Gly Gln Pro Gln Cys Ser Thr His Ile Leu Gln Trp Leu Lys Arg		
385	390	395
Val His Ala Asn Pro Leu Leu Ile Asp Val Val Thr Tyr Leu Val Ala		
405	410	415

Leu Ile Pro Glu Pro Ser Ala Gln Gln Leu Arg Glu Ile Phe Asn Met
 420 425 430

Ala Arg Asp Gln Arg Ser Arg Ala Thr Leu Tyr Ala Leu Ser His Ala
 435 440 445

Val Asn Asn Tyr His Lys Thr Asn Pro Thr Gly Thr Gln Glu Leu Leu
 450 455 460

Asp Ile Ala Asn Tyr Leu Met Glu Gln Ile Gln Asp Asp Cys Thr Gly
 465 470 475 480

Asp Glu Asp Tyr Thr Tyr Leu Ile Leu Arg Val Ile Gly Asn Met Gly
 485 490 495

Gln Thr Met Glu Gln Leu Thr Pro Glu Leu Lys Ser Ser Ile Leu Lys
 500 505 510

Cys Val Gln Ser Thr Lys Pro Ser Leu Met Ile Gln Lys Ala Ala Ile
 515 520 525

Gln Ala Leu Arg Lys Met Glu Pro Lys Asp Lys Asp Gln Glu Val Leu
 530 535 540

Leu Gln Thr Phe Leu Asp Asp Ala Ser Pro Gly Asp Lys Arg Leu Ala
 545 550 555 560

Ala Tyr Leu Met Leu Met Arg Ser Pro Ser Gln Ala Asp Ile Asn Lys
 565 570 575

Ile Val Gln Ile Leu Pro Trp Glu Gln Asn Glu Gln Val Lys Asn Phe
 580 585 590

Val Ala Ser His Ile Ala Asn Ile Leu Asn Ser Glu Glu Leu Asp Ile
 595 600 605

Gln Asp Leu Lys Lys Leu Val Lys Glu Ala Leu Lys Glu Ser Gln Leu
 610 615 620

Pro Thr Val Met Asp Phe Arg Lys Phe Ser Arg Asn Tyr Gln Leu Tyr
 625 630 635 640

Lys Ser Val Ser Leu Pro Ser Leu Asp Pro Ala Ser Ala Lys Ile Glu
 645 650 655

Gly Asn Leu Ile Phe Asp Pro Asn Asn Tyr Leu Pro Lys Glu Ser Met
660 665 670

Leu Lys Thr Thr Leu Thr Ala Phe Gly Phe Ala Ser Ala Asp Leu Ile
675 680 685

Glu Ile Gly Leu Glu Gly Lys Gly Phe Glu Pro Thr Leu Glu Ala Leu
690 695 700

Phe Gly Lys Gln Gly Phe Phe Pro Asp Ser Val Asn Lys Ala Leu Tyr
705 710 715 720

Trp Val Asn Gly Gln Val Pro Asp Gly Val Ser Lys Val Leu Val Asp
725 730 735

His Phe Gly Tyr Thr Lys Asp Asp Lys His Glu Gln Asp Met Val As n
740 745 750

Gly Ile Met Leu Ser Val Glu Lys Leu Ile Lys Asp Leu Lys Ser Lys
755 760 765

Glu Val Pro Glu Ala Arg Ala Tyr Leu Arg Ile Leu Gly Gl u Glu Leu
770 775 780

Gly Phe Ala Ser Leu His Asp Leu Gln Leu Leu Gly Lys Leu Leu Leu
785 790 795 800

Met Gly Ala Arg Thr Leu Gln Gly Ile Pro Gln Me t Ile Gly Glu Val
805 810 815

Ile Arg Lys Gly Ser Lys Asn Asp Phe Phe Leu His Tyr Ile Phe Met
820 825 830

Glu Asn Ala Phe Glu Leu Pro Thr Gly Al a Gly Leu Gln Leu Gln Ile
835 840 845

Ser Ser Ser Gly Val Ile Ala Pro Gly Ala Lys Ala Gly Val Lys Leu
850 855 860

Glu Val Ala Asn Met Gln Ala Gl u Leu Val Ala Lys Pro Ser Val Ser
865 870 875 880

Val Glu Phe Val Thr Asn Met Gly Ile Ile Ile Pro Asp Phe Ala Arg
885 890 895

Ser Gly Val Gln Met Asn Thr Asn Phe Phe His Glu Ser Gly Leu Glu
 900 905 910

Ala His Val Ala Leu Lys Ala Gly Lys Leu Lys Phe Ile Ile Pro Ser
 915 920 925

Pro Lys Arg Pro Val Lys Leu Leu Ser Gly Gly Asn Thr Leu His Leu
 930 935 940

Val Ser Thr Thr Lys Thr Glu Val Ile Pro Pro Leu Ile Glu Asn Arg
 945 950 955 960

Gln Ser Trp Ser Val Cys Lys Gln Val Phe Pro Gly Leu Asn Tyr Cys
 965 970 975

Thr Ser Gly Ala Tyr Ser Asn Ala Ser Ser Thr Asp Ser Ala Ser Tyr
 980 985 990

Tyr Pro Leu Thr Gly Asp Thr Arg Leu Glu Leu Glu Leu Arg Pro Thr
 995 1000 1005

Gly Glu Ile Glu Gln Tyr Ser Val Ser Ala Thr Tyr Glu Leu Gln
 1010 1015 1020

Arg Glu Asp Arg Ala Leu Val Asp Thr Leu Lys Phe Val Thr Gln
 1025 1030 1035

Ala Glu Gly Ala Lys Gln Thr Glu Ala Thr Met Thr Phe Lys Tyr
 1040 1045 1050

Asn Arg Gln Ser Met Thr Leu Ser Ser Glu Val Gln Ile Pro Asp
 1055 1060 1065

Phe Asp Val Asp Leu Gly Thr Ile Leu Arg Val Asn Asp Glu Ser
 1070 1075 1080

Thr Glu Gly Lys Thr Ser Tyr Arg Leu Thr Leu Asp Ile Gln Asn
 1085 1090 1095

Lys Lys Ile Thr Glu Val Ala Leu Met Gly His Leu Ser Cys Asp
 1100 1105 1110

Thr Lys Glu Glu Arg Lys Ile Lys Gly Val Ile Ser Ile Pro Arg
 1115 1120 1125

Leu Gln Ala Glu Ala Arg Ser Glu Ile Leu Ala His Trp Ser Pro

1130	1135	1140
Ala Lys Leu Leu Leu Gln Met	Asp Ser Ser Ala Thr	Ala Tyr Gly
1145	1150	1155
Ser Thr Val Ser Lys Arg Val	Ala Trp His Tyr Asp	Glu Glu Lys
1160	1165	1170
Ile Glu Phe Glu Trp Asn Thr	Gly Thr Asn Val Asp	Thr Lys Lys
1175	1180	1185
Met Thr Ser Asn Phe Pro Val	Asp Leu Ser Asp Tyr	Pro Lys Ser
1190	1195	1200
Leu His Met Tyr Ala Asn Arg	Leu Leu Asp His Arg	Val Pro Glu
1205	1210	1215
Thr Asp Met Thr Phe Arg His	Val Gly Ser Lys Leu	Ile Val Ala
1220	1225	1230
Met Ser Ser Trp Leu Gln Lys	Ala Ser Gly Ser Leu	Pro Tyr Thr
1235	1240	1245
Gln Thr Leu Gln Asp His Leu	Asn Ser Leu Lys Glu	Phe Asn Leu
1250	1255	1260
Gln Asn Met Gly Leu Pro Asp	Phe His Ile Pro Glu	Asn Leu Phe
1265	1270	1275
Leu Lys Ser Asp Gly Arg Val	Lys Tyr Thr Leu Asn	Lys Asn Ser
1280	1285	1290
Leu Lys Ile Glu Ile Pro Leu	Pro Phe Gly Gly Lys	Ser Ser Arg
1295	1300	1305
Asp Leu Lys Met Leu Glu Thr	Val Arg Thr Pro Ala	Leu His Phe
1310	1315	1320
Lys Ser Val Gly Phe His Leu	Pro Ser Arg Glu Phe	Gln Val Pro
1325	1330	1335
Thr Phe Thr Ile Pro Lys Leu	Tyr Gln Leu Gln Val	Pro Leu Leu
1340	1345	1350
Gly Val Leu Asp Leu Ser Thr	Asn Val Tyr Ser Asn	Leu Tyr Asn
1355	1360	1365

Trp Ser Ala Ser Tyr Ser Gly Gly Asn Thr Ser Thr Asp His Phe
 1370 1375 1380
 Ser Leu Arg Ala Arg Tyr His Met Lys Ala Asp Ser Val Val Asp
 1385 1390 1395
 Leu Leu Ser Tyr Asn Val Gln Gly Ser Gly Glu Thr Thr Tyr Asp
 1400 1405 1410
 His Lys Asn Thr Phe Thr Leu Ser Cys Asp Gly Ser Leu Arg His
 1415 1420 1425
 Lys Phe Leu Asp Ser Asn Ile Lys Phe Ser His Val Glu Lys Leu
 1430 1435 1440
 Gly Asn Asn Pro Val Ser Lys Gly Leu Leu Ile Phe Asp Ala Ser
 1445 1450 1455
 Ser Ser Trp Gly Pro Gln Met Ser Ala Ser Val His Leu Asp Ser
 1460 1465 1470
 Lys Lys Lys Gln His Leu Phe Val Lys Glu Val Lys Ile Asp Gly
 1475 1480 1485
 Gln Phe Arg Val Ser Ser Phe Tyr Ala Lys Gly Thr Tyr Gly Leu
 1490 1495 1500
 Ser Cys Gln Arg Asp Pro Asn Thr Gly Arg Leu Asn Gly Glu Ser
 1505 1510 1515
 Asn Leu Arg Phe Asn Ser Ser Tyr Leu Gln Gly Thr Asn Gln Ile
 1520 1525 1530
 Thr Gly Arg Tyr Glu Asp Gly Thr Leu Ser Leu Thr Ser Thr Ser
 1535 1540 1545
 Asp Leu Gln Ser Gly Ile Ile Lys Asn Thr Ala Ser Leu Lys Tyr
 1550 1555 1560
 Glu Asn Tyr Glu Leu Thr Leu Lys Ser Asp Thr Asn Gly Lys Tyr
 1565 1570 1575
 Lys Asn Phe Ala Thr Ser Asn Lys Met Asp Met Thr Phe Ser Lys
 1580 1585 1590

Gln Asn Ala Leu Leu Arg Ser Glu Tyr Gln Ala Asp Tyr Glu Ser
1595 1600 1605

Leu Arg Phe Phe Ser Leu Leu Ser Gly Ser Leu Asn Ser His Gly
1610 1615 1620

Leu Glu Leu Asn Ala Asp Ile Leu Gly Thr Asp Lys Ile Asn Ser
1625 1630 1635

Gly Ala His Lys Ala Thr Leu Arg Ile Gly Gln Asp Gly Ile Ser
1640 1645 1650

Thr Ser Ala Thr Thr Asn Leu Lys Cys Ser Leu Leu Val Leu Glu
1655 1660 1665

Asn Glu Leu Asn Ala Glu Leu Gly Leu Ser Gly Ala Ser Met Lys
1670 1675 1680

Leu Thr Thr Asn Gly Arg Phe Arg Glu His Asn Ala Lys Phe Ser
1685 1690 1695

Leu Asp Gly Lys Ala Ala Leu Thr Glu Leu Ser Leu Gly Ser Ala
1700 1705 1710

Tyr Gln Ala Met Ile Leu Gly Val Asp Ser Lys Asn Ile Phe Asn
1715 1720 1725

Phe Lys Val Ser Gln Glu Gly Leu Lys Leu Ser Asn Asp Met Met
1730 1735 1740

Gly Ser Tyr Ala Glu Met Lys Phe Asp His Thr Asn Ser Leu Asn
1745 1750 1755

Ile Ala Gly Leu Ser Leu Asp Phe Ser Ser Lys Leu Asp Asn Ile
1760 1765 1770

Tyr Ser Ser Asp Lys Phe Tyr Lys Gln Thr Val Asn Leu Gln Leu
1775 1780 1785

Gln Pro Tyr Ser Leu Val Thr Thr Leu Asn Ser Asp Leu Lys Tyr
1790 1795 1800

Asn Ala Leu Asp Leu Thr Asn Asn Gly Lys Leu Arg Leu Glu Pro
1805 1810 1815

Leu Lys Leu His Val Ala Gly Asn Leu Lys Gly Ala Tyr Gln Asn
 1820 1825 1830

Asn Glu Ile Lys His Ile Tyr Ala Ile Ser Ser Ala Ala Leu Ser
 1835 1840 1845

Ala Ser Tyr Lys Ala Asp Thr Val Ala Lys Val Gln Gly Val Glu
 1850 1855 1860

Phe Ser His Arg Leu Asn Thr Asp Ile Ala Gly Leu Ala Ser Ala
 1865 1870 1875

Ile Asp Met Ser Thr Asn Tyr Asn Ser Asp Ser Leu His Phe Ser
 1880 1885 1890

Asn Val Phe Arg Ser Val Met Ala Pro Phe Thr Met Thr Ile Asp
 1895 1900 1905

Ala His Thr Asn Gly Asn Gly Lys Leu Ala Leu Trp Gly Glu His
 1910 1915 1920

Thr Gly Gln Leu Tyr Ser Lys Phe Leu Leu Lys Ala Glu Pro Leu
 1925 1930 1935

Ala Phe Thr Phe Ser His Asp Tyr Lys Gly Ser Thr Ser His His
 1940 1945 1950

Leu Val Ser Arg Lys Ser Ile Ser Ala Ala Leu Glu His Lys Val
 1955 1960 1965

Ser Ala Leu Leu Thr Pro Ala Glu Gln Thr Gly Thr Trp Lys Leu
 1970 1975 1980

Lys Thr Gln Phe Asn Asn Asn Glu Tyr Ser Gln Asp Leu Asp Ala
 1985 1990 1995

Tyr Asn Thr Lys Asp Lys Ile Gly Val Glu Leu Thr Gly Arg Thr
 2000 2005 2010

Leu Ala Asp Leu Thr Leu Leu Asp Ser Pro Ile Lys Val Pro Leu
 2015 2020 20 25

Leu Leu Ser Glu Pro Ile Asn Ile Ile Asp Ala Leu Glu Met Arg
 2030 2035 2040

Asp Ala Val Glu Lys Pro Gln Glu Phe Thr Ile Val Ala Phe Val

10/22

2045	2050	2055
Lys Tyr Asp Lys Asn Gln Asp	Val His Ser Ile Asn	Leu Pro Phe
2060	2065	2070
Phe Glu Thr Leu Gln Glu Tyr	Phe Glu Arg Asn Arg	Gln Thr Ile
2075	2080	2085
Ile Val Val Val Glu Asn Val	Gln Arg Asn Leu Lys	His Ile Asn
2090	2095	2100
Ile Asp Gln Phe Val Arg Lys	Tyr Arg Ala Ala Leu	Gly Lys Leu
2105	2110	2115
Pro Gln Gln Ala Asn Asp Tyr	Leu Asn Ser Phe Asn	Trp Glu Arg
2120	2125	2130
Gln Val Ser His Ala Lys Glu	Lys Leu Thr Ala Leu	Thr Lys Lys
2135	2140	2145
Tyr Arg Ile Thr Glu Asn Asp	Ile Gln Ile Ala Leu	Asp Asp Ala
2150	2155	2160
Lys Ile Asn Phe Asn Glu Lys	Leu Ser Gln Leu Gln	Thr Tyr Met
2165	2170	2175
Ile Gln Phe Asp Gln Tyr Ile	Lys Asp Ser Tyr Asp	Leu His Asp
2180	2185	2190
Leu Lys Ile Ala Ile Ala Asn	Ile Ile Asp Glu Ile	Ile Glu Lys
2195	2200	2205
Leu Lys Ser Leu Asp Glu His	Tyr His Ile Arg Val	Asn Leu Val
2210	2215	2220
Lys Thr Ile His Asp Leu His	Leu Phe Ile Glu Asn	Ile Asp Phe
2225	2230	2235
Asn Lys Ser Gly Ser Ser Thr	Ala Ser Trp Ile Gln	Asn Val Asp
2240	2245	2250
Thr Lys Tyr Gln Ile Arg Ile	Gln Ile Gln Glu Lys	Leu Gln Gln
2255	2260	2265
Leu Lys Arg His Ile Gln Asn	Ile Asp Ile Gln His	Leu Ala Gly
2270	2275	2280

Lys Leu	Lys Gln His Ile Glu	Ala Ile Asp Val Arg	Val Leu Leu
2285	2290	2295	
Asp Gln	Leu Gly Thr Thr Ile	Ser Phe Glu Arg Ile	Asn Asp Val
2300	2305	2310	
Leu Glu	His Val Lys His Phe	Val Ile Asn Leu Ile	Gly Asp Phe
2315	2320	2325	
Glu Val	Ala Glu Lys Ile Asn	Ala Phe Arg Ala Lys	Val His Glu
2330	2335	2340	
Leu Ile	Glu Arg Tyr Glu Val	Asp Gln Gln Ile Gln	Val Leu Met
2345	2350	2355	
Asp Lys	Leu Val Glu Leu Thr	His Gln Tyr Lys Leu	Lys Glu Thr
2360	2365	2370	
Ile Gln	Lys Leu Ser Asn Val	Leu Gln Gln Val Lys	Ile Lys Asp
2375	2380	2385	
Tyr Phe	Glu Lys Leu Val Gly	Phe Ile Asp Asp Ala	Val Lys Lys
2390	2395	2400	
Leu Asn	Glu Leu Ser Phe Lys	Thr Phe Ile Glu Asp	Val Asn Lys
2405	2410	2415	
Phe Leu	Asp Met Leu Ile Lys	Lys Leu Lys Ser Phe	Asp Tyr His
2420	2425	2430	
Gln Phe	Val Asp Glu Thr Asn	Asp Lys Ile Arg Glu	Val Thr Gln
2435	2440	2445	
Arg Leu	Asn Gly Glu Ile Gln	Ala Leu Glu Leu Pro	Gln Lys Ala
2450	2455	2460	
Glu Ala	Leu Lys Leu Phe Leu	Glu Glu Thr Lys Ala	Thr Val Ala
2465	2470	2475	
Val Tyr	Leu Glu Ser Leu Gln	Asp Thr Lys Ile Thr	Leu Ile Ile
2480	2485	2490	
Asn Trp	Leu Gln Glu Ala Leu	Ser Ser Ala Ser Leu	Ala His Met
2495	2500	2505	

Lys Ala 2510	Lys Phe Arg Glu Thr 2515	Leu Glu Asp Thr Arg 2520	Asp Arg Met
Tyr Gln 2525	Met Asp Ile Gln Gln 2530	Glu Leu Gln Arg Tyr 2535	Leu Ser Leu
Val Gly 2540	Gln Val Tyr Ser Thr 2545	Leu Val Thr Tyr Ile 2550	Ser Asp Trp
Trp Thr 2555	Leu Ala Ala Lys Asn 2560	Leu Thr Asp Phe Ala 2565	Glu Gln Tyr
Ser Ile 2570	Gln Asp Trp Ala Lys 2575	Arg Met Lys Ala Leu 2580	Val Glu Gln
Gly Phe 2585	Thr Val Pro Glu Ile 2590	Lys Thr Ile Leu Gly 2595	Thr Met Pro
Ala Phe 2600	Glu Val Ser Leu Gln 2605	Ala Leu Gln Lys Ala 2610	Thr Phe Gln
Thr Pro 2615	Asp Phe Ile Val Pro 2620	Leu Thr Asp Leu Arg 2625	Ile Pro Ser
Val Gln 2630	Ile Asn Phe Lys Asp 2635	Leu Lys Asn Ile Lys 2640	Ile Pro Ser
Arg Phe 2645	Ser Thr Pro Glu Phe 2650	Thr Ile Leu Asn Thr 2655	Phe His Ile
Pro Ser 2660	Phe Thr Ile Asp Phe 2665	Val Glu Met Lys Val 2670	Lys Ile Ile
Arg Thr 2675	Ile Asp Gln Met Gln 2680	Asn Ser Glu Leu Gln 2685	Trp Pro Val
Pro Asp 2690	Ile Tyr Leu Arg Asp 2695	Leu Lys Val Glu Asp 2700	Ile Pro Leu
Ala Arg 2705	Ile Thr Leu Pro Asp 2710	Phe Arg Leu Pro Glu 2715	Ile Ala Ile
Pro Glu 2720	Phe Ile Ile Pro Thr 2725	Leu Asn Leu Asn Asp 2730	Phe Gln Val

Pro Asp Leu His Ile Pro Glu Phe Gln Leu Pro His Ile Ser His
 2735 2740 2745
 Thr Ile Glu Val Pro Thr Phe Gly Lys Leu Tyr Ser Ile Leu Lys
 2750 2755 2760
 Ile Gln Ser Pro Leu Phe Thr Leu Asp Ala Asn Ala Asp Ile Gly
 2765 2770 2775
 Asn Gly Thr Thr Ser Ala Asn Glu Ala Gly Ile Ala Ala Ser Ile
 2780 2785 2790
 Thr Ala Lys Gly Glu Ser Lys Leu Glu Val Leu Asn Phe Asp Phe
 2795 2800 2805
 Gln Ala Asn Ala Gln Leu Ser Asn Pro Lys Ile Asn Pro Leu Ala
 2810 2815 2820
 Leu Lys Glu Ser Val Lys Phe Ser Ser Lys Tyr Leu Arg Thr Glu
 2825 2830 2835
 His Gly Ser Glu Met Leu Phe Phe Gly Asn Ala Ile Glu Gly Lys
 2840 2845 2850
 Ser Asn Thr Val Ala Ser Leu His Thr Glu Lys Asn Thr Leu Glu
 2855 2860 2865
 Leu Ser Asn Gly Val Ile Val Lys Ile Asn Asn Gln Leu Thr Leu
 2870 2875 2880
 Asp Ser Asn Thr Lys Tyr Phe His Lys Leu Asn Ile Pro Lys Leu
 2885 2890 2895
 Asp Phe Ser Ser Gln Ala Asp Leu Arg Asn Glu Ile Lys Thr Leu
 2900 2905 2910
 Leu Lys Ala Gly His Ile Ala Trp Thr Ser Ser Gly Lys Gly Ser
 2915 2920 2925
 Trp Lys Trp Ala Cys Pro Arg Phe Ser Asp Glu Gly Thr His Glu
 2930 2935 2940
 Ser Gln Ile Ser Phe Thr Ile Glu Gly Pro Leu Thr Ser Phe Gly
 2945 2950 2955
 Leu Ser Asn Lys Ile Asn Ser Lys His Leu Arg Val Asn Gln Asn

2960	2965	2970
Leu Val Tyr Glu Ser Gly Ser 2975	Leu Asn Phe Ser Lys 2980	Leu Glu Ile 2985
Gln Ser Gln Val Asp Ser 2990	Gln His Val Gly His 2995	Ser Val Leu Thr 3000
Ala Lys Gly Met Ala Leu Phe 3005	Gly Glu Gly Lys 3010	Ala Glu Phe Thr 3015
Gly Arg His Asp Ala His 3020	Leu Asn Gly Lys Val 3025	Ile Gly Thr Leu 3030
Lys Asn Ser Leu Phe Phe Ser 3035	Ala Gln Pro Phe 3040	Glu Ile Thr Ala 3045
Ser Thr Asn Asn Glu Gly Asn 3050	Leu Lys Val Arg 3055	Phe Pro Leu Arg 3060
Leu Thr Gly Lys Ile Asp Phe 3065	Leu Asn Asn Tyr 3070	Ala Leu Phe Leu 3075
Ser Pro Ser Ala Gln Gln Ala 3080	Ser Trp Gln Val 3085	Ser Ala Arg Phe 3090
Asn Gln Tyr Lys Tyr Asn Gln 3095	Asn Phe Ser Ala 3100	Gly Asn Asn Glu 3105
Asn Ile Met Glu Ala His Val 3110	Gly Ile Asn Gly 3115	Glu Ala Asn Leu 3120
Asp Phe Leu Asn Ile Pro Leu 3125	Thr Ile Pro Glu 3130	Met Arg Leu Pro 3135
Tyr Thr Ile Ile Thr Thr Pro 3140	Pro Leu Lys Asp 3145	Phe Ser Leu Trp 3150
Glu Lys Thr Gly Leu Lys Glu 3155	Phe Leu Lys Thr 3160	Thr Lys Gln Ser 3165
Phe Asp Leu Ser Val Lys Ala 3170	Gln Tyr Lys Lys 3175	Asn Lys His Arg 3180
His Ser Ile Thr Asn Pro Leu 3185	Ala Val Leu Cys 3190	Glu Phe Ile Ser 3195

Gln Ser Ile Lys Ser Phe Asp Arg His Phe Glu Lys Asn Arg Asn
 3200 3205 3210
 Asn Ala Leu Asp Phe Val Thr Lys Ser Tyr Asn Glu Thr Lys Ile
 3215 3220 3225
 Lys Phe Asp Lys Tyr Lys Ala Glu Lys Ser His Asp Glu Leu Pro
 3230 3235 3240
 Arg Thr Phe Gln Ile Pro Gly Tyr Thr Val Pro Val Val Asn Val
 3245 3250 3255
 Glu Val Ser Pro Phe Thr Ile Glu Met Ser Ala Phe Gly Tyr Val
 3260 3265 3270
 Phe Pro Lys Ala Val Ser Met Pro Ser Phe Ser Ile Leu Gly Ser
 3275 3280 3285
 Asp Val Arg Val Pro Ser Tyr Thr Leu Ile Leu Pro Ser Leu Glu
 3290 3295 3300
 Leu Pro Val Leu His Val Pro Arg Asn Leu Lys Leu Ser Leu Pro
 3305 3310 3315
 His Phe Lys Glu Leu Cys Thr Ile Ser His Ile Phe Ile Pro Ala
 3320 3325 3330
 Met Gly Asn Ile Thr Tyr Asp Phe Ser Phe Lys Ser Ser Val Ile
 3335 3340 3345
 Thr Leu Asn Thr Asn Ala Glu Leu Phe Asn Gln Ser Asp Ile Val
 3350 3355 3360
 Ala His Leu Leu Ser Ser Ser Ser Ser Val Ile Asp Ala Leu Gln
 3365 3370 3375
 Tyr Lys Leu Glu Gly Thr Thr Arg Leu Thr Arg Lys Arg Gly Leu
 3380 3385 3390
 Lys Leu Ala Thr Ala Leu Ser Leu Ser Asn Lys Phe Val Glu Gly
 3395 3400 3405
 Ser His Asn Ser Thr Val Ser Leu Thr Thr Lys Asn Met Glu Val
 3410 3415 3420

Ser Val Ala Lys Thr Thr Lys Ala Glu Ile Pro Ile Leu Arg Met
 3425 3430 3435
 Asn Phe Lys Gln Glu Leu Asn Gly Asn Thr Lys Ser Lys Pro Thr
 3440 3445 3450
 Val Ser Ser Ser Met Glu Phe Lys Tyr Asp Phe Asn Ser Ser Met
 3455 3460 3465
 Leu Tyr Ser Thr Ala Lys Gly Ala Val Asp His Lys Leu Ser Leu
 3470 3475 3480
 Glu Ser Leu Thr Ser Tyr Phe Ser Ile Glu Ser Ser Thr Lys Gly
 3485 3490 3495
 Asp Val Lys Gly Ser Val Leu Ser Arg Glu Tyr Ser Gly Thr Ile
 3500 3505 3510
 Ala Ser Glu Ala Asn Thr Tyr Leu Asn Ser Lys Ser Thr Arg Ser
 3515 3520 3525
 Ser Val Lys Leu Gln Gly Thr Ser Lys Ile Asp Asp Ile Trp Asn
 3530 3535 3540
 Leu Glu Val Lys Glu Asn Phe Ala Gly Glu Ala Thr Leu Gln Arg
 3545 3550 3555
 Ile Tyr Ser Leu Trp Glu His Ser Thr Lys Asn His Leu Gln Leu
 3560 3565 3570
 Glu Gly Leu Phe Phe Thr Asn Gly Glu His Thr Ser Lys Ala Thr
 3575 3580 3585
 Leu Glu Leu Ser Pro Trp Gln Met Ser Ala Leu Val Gln Val His
 3590 3595 3600
 Ala Ser Gln Pro Ser Ser Phe His Asp Phe Pro Asp Leu Gly Gln
 3605 3610 3615
 Glu Val Ala Leu Asn Ala Asn Thr Lys Asn Gln Lys Ile Arg Trp
 3620 3625 3630
 Lys Asn Glu Val Arg Ile His Ser Gly Ser Phe Gln Ser Gln Val
 3635 3640 3645

Glu Leu Ser Asn Asp Gln Glu Lys Ala His Leu Asp Ile Ala Gly
 3650 3655 3660
 Ser Leu Glu Gly His Leu Arg Phe Leu Lys Asn Ile Ile Leu Pro
 3665 3670 3675
 Val Tyr Asp Lys Ser Leu Trp Asp Phe Leu Lys Leu Asp Val Thr
 3680 3685 3690
 Thr Ser Ile Gly Arg Arg Gln His Leu Arg Val Ser Thr Ala Phe
 3695 3700 3705
 Val Tyr Thr Lys Asn Pro Asn Gly Tyr Ser Phe Ser Ile Pro Val
 3710 3715 3720
 Lys Val Leu Ala Asp Lys Phe Ile Thr Pro Gly Leu Lys Leu Asn
 3725 3730 3735
 Asp Leu Asn Ser Val Leu Val Met Pro Thr Phe His Val Pro Phe
 3740 3745 3750
 Thr Asp Leu Gln Val Pro Ser Cys Lys Leu Asp Phe Arg Glu Ile
 3755 3760 3765
 Gln Ile Tyr Lys Lys Leu Arg Thr Ser Ser Phe Ala Leu Asn Leu
 3770 3775 3780
 Pro Thr Leu Pro Glu Val Lys Phe Pro Glu Val Asp Val Leu Thr
 3785 3790 3795
 Lys Tyr Ser Gln Pro Glu Asp Ser Leu Ile Pro Phe Phe Glu Ile
 3800 3805 3810
 Thr Val Pro Glu Ser Gln Leu Thr Val Ser Gln Phe Thr Leu Pro
 3815 3820 3825
 Lys Ser Val Ser Asp Gly Ile Ala Ala Leu Asp Leu Asn Ala Val
 3830 3835 3840
 Ala Asn Lys Ile Ala Asp Phe Glu Leu Pro Thr Ile Ile Val Pro
 3845 3850 3855
 Glu Gln Thr Ile Glu Ile Pro Ser Ile Lys Phe Ser Val Pro Ala
 3860 3865 3870
 Gly Ile Val Ile Pro Ser Phe Gln Ala Leu Thr Ala Arg Phe Glu

3875	3880	3885
Val Asp 3890	Ser Pro Val Tyr Asn 3895	Ala Thr Trp Ser Ala 3900
Asn Lys 3905	Ala Asp Tyr Val Glu 3910	Thr Val Leu Asp Ser 3915
Ser Thr 3920	Val Gln Phe Leu Glu 3925	Tyr Glu Leu Asn Val 3930
His Lys 3935	Ile Glu Asp Gly Thr 3940	Leu Ala Ser Lys Thr 3945
Leu Ala 3950	His Arg Asp Phe Ser 3955	Ala Glu Tyr Glu Glu 3960
Phe Glu 3965	Gly Leu Gln Glu Trp 3970	Glu Gly Lys Ala His 3975
Lys Ser 3980	Pro Ala Phe Thr Asp 3985	Leu His Leu Arg Tyr 3990
Lys Lys 3995	Gly Ile Ser Thr Ser 4000	Ala Ala Ser Pro Ala 4005
Val Gly 4010	Met Asp Met Asp Glu 4015	Asp Asp Asp Phe Ser 4020
Phe Tyr 4025	Tyr Ser Pro Gln Ser 4030	Ser Pro Asp Lys Lys 4035
Phe Lys 4040	Thr Glu Leu Arg Val 4045	Arg Glu Ser Asp Glu 4050
Ile Lys 4055	Val Asn Trp Glu Glu 4060	Glu Ala Ala Ser Gly 4065
Ser Leu 4070	Lys Asp Asn Val Pro 4075	Lys Ala Thr Gly Val 4080
Tyr Val 4085	Asn Lys Tyr His Trp 4090	Glu His Thr Gly Leu 4095
Glu Val 4100	Ser Ser Lys Leu Arg 4105	Arg Asn Leu Gln Asn 4110

Trp Val Tyr Gln Gly Ala Ile Arg Gln Ile Asp Asp Ile Asp Val
 4115 4120 4125
 Arg Phe Gln Lys Ala Ala Ser Gly Thr Thr Gly Thr Tyr Gln Glu
 4130 4135 4140
 Trp Lys Asp Lys Ala Gln Asn Leu Tyr Gln Glu Leu Leu Thr Gln
 4145 4150 4155
 Glu Gly Gln Ala Ser Phe Gln Gly Leu Lys Asp Asn Val Phe Asp
 4160 4165 4170
 Gly Leu Val Arg Val Thr Gln Lys Phe His Met Lys Val Lys His
 4175 4180 4185
 Leu Ile Asp Ser Leu Ile Asp Phe Leu Asn Phe Pro Arg Phe Gln
 4190 4195 4200
 Phe Pro Gly Lys Pro Gly Ile Tyr Thr Arg Glu Glu Leu Cys Thr
 4205 4210 4215
 Met Phe Ile Arg Glu Val Gly Thr Val Leu Ser Gln Val Tyr Ser
 4220 4225 4230
 Lys Val His Asn Gly Ser Glu Ile Leu Phe Ser Tyr Phe Gln Asp
 4235 4240 4245
 Leu Val Ile Thr Leu Pro Phe Glu Leu Arg Lys His Lys Leu Ile
 4250 4255 4260
 Asp Val Ile Ser Met Tyr Arg Glu Leu Leu Lys Asp Leu Ser Lys
 4265 4270 4275
 Glu Ala Gln Glu Val Phe Lys Ala Ile Gln Ser Leu Lys Thr Thr
 4280 4285 4290
 Glu Val Leu Arg Asn Leu Gln Asp Leu Leu Gln Phe Ile Phe Gln
 4295 4300 4305
 Leu Ile Glu Asp Asn Ile Lys Gln Leu Lys Glu Met Lys Phe Thr
 4310 4315 4320
 Tyr Leu Ile Asn Tyr Ile Gln Asp Glu Ile Asn Thr Ile Phe A sn
 4325 4330 4335

Asp Tyr Ile Pro Tyr Val Phe Lys Leu Leu Lys Glu Asn Leu Cys
4340 4345 4350

Leu Asn Leu His Lys Phe Asn Glu Phe Ile Gln Asn Glu Leu Gln
4355 4360 4365

Glu Ala Ser Gln Glu Leu Gln Gln Ile His Gln Tyr Ile Met Ala
4370 4375 4380

Leu Arg Glu Glu Tyr Phe Asp Pro Ser Ile Val Gly Trp Thr Val
4385 4390 4395

Lys Tyr Tyr Glu Leu Glu Glu Lys Ile Val Ser Leu Ile Lys Asn
4400 4405 4410

Leu Leu Val Ala Leu Lys Asp Phe His Ser Glu Tyr Ile Val Ser
4415 4420 4425

Ala Ser Asn Phe Thr Ser Gln Leu Ser Ser Gln Val Glu Gln Phe
4430 4435 4440

Leu His Arg Asn Ile Gln Glu Tyr Leu Ser Ile Leu Thr Asp Pro
4445 4450 4455

Asp Gly Lys Gly Lys Glu Lys Ile Ala Glu Leu Ser Ala Thr Ala
4460 4465 4470

Gln Glu Ile Ile Lys Ser Gln Ala Ile Ala Thr Lys Lys Ile Ile
4475 4480 4485

Ser Asp Tyr His Gln Gln Phe Arg Tyr Lys Leu Gln Asp Phe Ser
4490 4495 4500

Asp Gln Leu Ser Asp Tyr Tyr Glu Lys Phe Ile Ala Glu Ser Lys
4505 4510 4515

Arg Leu Ile Asp Leu Ser Ile Gln Asn Tyr His Thr Phe Leu Ile
4520 4525 4530

Tyr Ile Thr Glu Leu Leu Lys Lys Leu Gln Ser Thr Thr Val Met
4535 4540 4545

Asn Pro Tyr Met Lys Leu Ala Pro Gly Glu Leu Thr Ile Ile Leu
4550 4555 4560

<210> 2
 <211> 317
 <212> PRT
 <213> Homo sapiens

<400> 2

Met Lys Val Leu Trp Ala Ala Leu Leu Val Thr Phe Leu Ala Gly Cys
 1 5 10 15

Gln Ala Lys Val Glu Gln Ala Val Glu Thr Glu Pro Glu Pro Glu Leu
 20 25 30

Arg Gln Gln Thr Glu Trp Gln Ser Gly Gln Arg Trp Glu Leu Ala Leu
 35 40 45

Gly Arg Phe Trp Asp Tyr Leu Arg Trp Val Gln Thr Leu Ser Glu Gln
 50 55 60

Val Gln Glu Glu Leu Leu Ser Ser Gln Val Thr Gln Glu Leu Arg Ala
 65 70 75 80

Leu Met Asp Glu Thr Met Lys Glu Leu Lys Ala Tyr Lys Ser Glu Leu
 85 90 95

Glu Glu Gln Leu Thr Pro Val Ala Glu Glu Thr Arg Ala Arg Leu Ser
 100 105 110

Lys Glu Leu Gln Ala Ala Gln Ala Arg Leu Gly Ala Asp Met Glu Asp
 115 120 125

Val Cys Gly Arg Leu Val Gln Tyr Arg Gly Glu Val Gln Ala Met Leu
 130 135 140

Gly Gln Ser Thr Glu Glu Leu Arg Val Arg Leu Ala Ser His Le u Arg
 145 150 155 160

Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala Asp Asp Leu Gln Lys Arg
 165 170 175

Leu Ala Val Tyr Gln Ala Gly Ala Arg Glu Gly Ala Gl u Arg Gly Leu
 180 185 190

Ser Ala Ile Arg Glu Arg Leu Gly Pro Leu Val Glu Gln Gly Arg Val
 195 200 205

Arg Ala Ala Thr Val Gly Ser Leu Ala Gly Gl n Pro Leu Gln Glu Arg
 210 215 220

Ala Gln Ala Trp Gly Glu Arg Leu Arg Ala Arg Met Glu Glu Met Gly
225 230 235 240

Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu Gln Val Ala Glu
245 250 255

Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile Arg Leu Gln Ala
260 265 270

Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu Pro Leu Val Glu
275 280 285

Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys Val Gln Ala Ala
290 295 300

Val Gly Thr Ser Ala Ala Pro Val Pro Ser Asp Asn His
305 310 315

<210> 3
<211> 11
<212> PRT
<213> synthetic construct

<400> 3

Glu Asn Phe Ala Gly Glu Ala Thr Leu Gln Arg
1 5 10

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/051170

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/68 G01N33/92 C12Q1/68 A61K31/00 A61K38/00
A61K39/00
//C07K14/775

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, EMBASE, BIOSIS, COMPENDEX

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>LINGAPPA VR ET AL: "Translocational pausing and the regulation of membrane protein biogenesis"</p> <p>MEMBRANE PROTEINS: STRUCTURE, FUNCTION AND EXPRESSION CONTROL KYUSHU UNIVERSITY PRESS, 7-1-146, HAKOZAKI, HIGASHI-KU, FUKUOKA 812, JAPAN; S. KARGER AG, P.O. BOX, ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND, 1997, pages 93-100, XP001183818</p> <p>& INTERNATIONAL SYMPOSIUM</p> <p>ISSN: 3-8055-6465-1</p> <p>page 95, paragraph 4 - page 97, paragraph 2; figure 2</p> <p style="text-align: center;">----- -/--</p>	1-28

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

6 October 2004

Date of mailing of the international search report

02/11/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Jenn, T

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/051170

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CLAVEY V ET AL: "INTERACTION ENTRE LE LDL-RECEPTEUR ET LES LIPOPROTEINES CONTENANT DE L'APO B INTERACTION BETWEEN THE LDL RECEPTOR AND THE LIPOPROTEINS CONTAINING APOB" ANNALES D'ENDOCRINOLOGIE, MASSON, PARIS, FR, vol. 52, no. 6, 1991, pages 459-463, XP001029770 ISSN: 0003-4266 cited in the application abstract	1-28
Y	BAUMANN, MARC H. ET AL: "Apolipoprotein E includes a binding site which is recognized by several amyloidogenic polypeptides" BIOCHEMICAL JOURNAL, vol. 349, no. 1, 1 July 2000 (2000-07-01), pages 77-84, XP002262330 cited in the application abstract; figures 2,4 page 78, column 1, paragraph 4	1,3
Y	WO 02/065133 A (SALAMA ABDULGABAR; KIESEWETTER HOLGER (DE)) 22 August 2002 (2002-08-22) cited in the application abstract; claim 1; examples 11-13	1,3
Y	WO 03/005037 A (STEFAS ELIE ;APOH TECHNOLOGIES SA (FR)) 16 January 2003 (2003-01-16) cited in the application page 2, line 19 - line 26 abstract; claims 1-3	1,3
X	US 2002/155426 A1 (BALES KELLY R ET AL) 24 October 2002 (2002-10-24) cited in the application abstract; claims 1,4,22,23 paragraphs '0009!', '0055!	2-6,9-14
A	WO 97/14437 A (WEISGRABER KARL H ;MAHLEY ROBERT W (US); PITAS ROBERT E (US); UNIV) 24 April 1997 (1997-04-24) cited in the application abstract; claims 1,2,7,11-14 page 5, line 5 page 11, line 7 - line 20 page 13, line 1 - line 20 page 21, line 7 - line 16	9-14

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/051170

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99/15159 A (NOVA MOLECULAR INC) 1 April 1999 (1999-04-01) cited in the application abstract; claims 1,17,19,24,31,32,36 -----	9-14
A	US 6 462 171 B1 (SOTO-JARA CLAUDIO ET AL) 8 October 2002 (2002-10-08) abstract; claims 1,3,5,13,15 column 13, line 45 - line 58 -----	9-14
A	US 6 022 683 A (POIRIER JUDES) 8 February 2000 (2000-02-08) cited in the application abstract; claims 1-4,13,14 column 3, line 4 - line 8 column 3, line 59 - line 63 column 6, line 7 - line 16 -----	16-18,28
A	DIEDRICH, JANE F. ET AL: "Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E-- and cathepsin D in astrocytes" JOURNAL OF VIROLOGY, vol. 65, no. 9, September 1991 (1991-09), pages 4759-4768, XP000443989 cited in the application abstract page 4759, column 2, line 5 - line 10 page 4764, column 2; figures 3,4 -----	16-18,28
A	CHOE, LEILA H. ET AL: "Apolipoprotein E and other cerebrospinal fluid proteins differentiate ante mortem variant Creutzfeldt-Jakob disease from ante mortem sporadic Creutzfeldt-Jakob disease" ELECTROPHORESIS, vol. 23, no. 14, 14 July 2002 (2002-07-14), pages 2242-2246, XP002262331 cited in the application abstract page 2242, column 1, paragraph 1 - column 2, paragraph 1 page 2244, column 2, paragraph 2 ----- -/--	16-18,28

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/EP2004/051170

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>GOLAZ OLIVIER ET AL: "Phenotyping of apolipoprotein E using immobilized pH gradient gels for one-dimensional and two-dimensional separations" ELECTROPHORESIS, vol. 16, no. 7, 1995, pages 1184-1186, XP009021630 ISSN: 0173-0835 cited in the application abstract</p>	16-18,28
A	<p>LUCASSEN RALF ET AL: "In vitro amplification of protease-resistant prion protein requires free sulfhydryl groups" BIOCHEMISTRY;BIOCHEMISTRY APR 15 2003, vol. 42, no. 14, 15 April 2003 (2003-04-15), pages 4127-4135, XP002262517 cited in the application abstract</p>	1-8
A	<p>ENARI M FLECHSIG E WEISSMANN C: "Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 16, 31 July 2001 (2001-07-31), pages 9295-9299, XP002959455 ISSN: 0027-8424 cited in the application abstract</p>	1-8
P,A	<p>US 2004/018554 A1 (GREEN LARRY R) 29 January 2004 (2004-01-29) abstract; claims 13-15</p>	1-8

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 15 to 18 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.2

Claims Nos.: 12,22,26

Present claims 12, 22 and 26 relate to an extremely large number of possible use/method/assay. In fact, the claims contain so many options and variables that a lack of clarity (and conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claim impossible. Moreover, there is no SEQ ID provided for the fragments of the sequences disclosed in said claims 12, 22 and 26 (Rule 5.2 PCT), and said fragments are defined by reference to a parameter ("is of a molecular weight selected from 30 and 40 kDa). The use of this parameters in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to compare the parameters the applicant has chosen to employ with what is set out in the prior art. The lack of clarity is such as to render a meaningful complete search impossible.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/051170

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 15-18
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 15 to 18 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 12, 22, 26
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP2004/051170

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02065133	A	22-08-2002	DE 10107083 A1	29-08-2002
			WO 02065133 A2	22-08-2002
			EP 1360502 A2	12-11-2003
			JP 2004518966 T	24-06-2004
			US 2004096902 A1	20-05-2004
WO 03005037	A	16-01-2003	FR 2827047 A1	10-01-2003
			CA 2450937 A1	16-01-2003
			EP 1402269 A1	31-03-2004
			WO 03005037 A1	16-01-2003
			US 2004171071 A1	02-09-2004
US 2002155426	A1	24-10-2002	US 6428950 B1	06-08-2002
			AU 1742200 A	13-06-2000
			CA 2349229 A1	02-06-2000
			EP 1133699 A1	19-09-2001
			JP 2002530122 T	17-09-2002
			WO 0031548 A1	02-06-2000
WO 9714437	A	24-04-1997	AU 718498 B2	13-04-2000
			AU 5297696 A	07-05-1997
			CA 2233848 A1	24-04-1997
			EP 0862460 A1	09-09-1998
			JP 2001517198 T	02-10-2001
			WO 9714437 A1	24-04-1997
			US 2002009439 A1	24-01-2002
WO 9915159	A	01-04-1999	AU 9454098 A	12-04-1999
			CA 2304505 A1	01-04-1999
			EP 1017375 A2	12-07-2000
			WO 9915159 A2	01-04-1999
			JP 2001517617 T	09-10-2001
			US 6274603 B1	14-08-2001
			US 2001051602 A1	13-12-2001
US 6462171	B1	08-10-2002	US 5948763 A	07-09-1999
			US 2003087407 A1	08-05-2003
			AU 715662 B2	10-02-2000
			AU 6112996 A	30-12-1996
			CA 2222690 A1	19-12-1996
			EP 0843516 A1	27-05-1998
			JP 2001519753 T	23-10-2001
			WO 9639834 A1	19-12-1996
US 6022683	A	08-02-2000	AT 269978 T	15-07-2004
			AU 5571798 A	15-07-1998
			AU 745073 B2	14-03-2002
			AU 5675798 A	15-07-1998
			CA 2275404 A1	25-06-1998
			CA 2275504 A1	25-06-1998
			DE 69729473 D1	15-07-2004
			DE 69729654 D1	29-07-2004
			EP 0948647 A1	13-10-1999
			EP 0946753 A2	06-10-1999
			WO 9827226 A2	25-06-1998
			WO 9827227 A2	25-06-1998
			JP 2001524809 T	04-12-2001

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/051170

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2004018554	A1	29-01-2004	NONE

THIS PAGE BLANK (USPTO)